Leading articles
| From the Current Issue: December 1 2009; 64 (6) [Table of Contents] |
- Matthew Dryden, Kieran Hand, Peter Davey, and on behalf of the BSAC Council
- Antibiotics for community-acquired pneumonia
J. Antimicrob. Chemother. 2009. 64:1123-1125.[Abstract] [Full Text] [PDF]
- Asgeir Johannessen, Marius Troseid, and Alexandra Calmy
- Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings
J. Antimicrob. Chemother. 2009. 64:1126-1129.[Abstract] [Full Text] [PDF]
| From Past Issues: |
- Matthew S. Dryden, Jonathan Cooke, and Peter Davey
- Antibiotic stewardship—more education and regulation not more availability?
J. Antimicrob. Chemother. 2009. 64:885-888.[Abstract] [Full Text] [PDF]
- Gavin D. Barlow and on behalf of the BSAC Council
- Swine flu and antibiotics
J. Antimicrob. Chemother. 2009. 64:889-894.[Abstract] [Full Text] [PDF]
- F. Martin and G. P. Taylor
- The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is ‘the more the merrier’?
J. Antimicrob. Chemother. 2009. 64:895-900.[Abstract] [Full Text] [PDF]
- Christopher McGuigan and Jan Balzarini
- FV100 as a new approach for the possible treatment of varicella-zoster virus infection
J. Antimicrob. Chemother. 2009. 64:671-673.[Abstract] [Full Text] [PDF]
- Jake Dunning and Mark Nelson
- Novel strategies to treat antiretroviral-naive HIV-infected patients
J. Antimicrob. Chemother. 2009. 64:674-679.[Abstract] [Full Text] [PDF]
- Giovanni Guaraldi and Ioannis G. Baraboutis
- Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities
J. Antimicrob. Chemother. 2009. 64:437-440.[Abstract] [Full Text] [PDF]
- Stephen Taylor, Ashini Jayasuriya, and Erasmus Smit
- Using HIV resistance tests in clinical practice
J. Antimicrob. Chemother. 2009. 64:218-222.[Abstract] [Full Text] [PDF]
- Vincent Wai-Sun Wong and Joseph Jao-Yiu Sung
- Antiviral therapy for chronic hepatitis B: are we doing any good to patients?
J. Antimicrob. Chemother. 2009. 64:223-226.[Abstract] [Full Text] [PDF]
- Martin Sundqvist and Gunnar Kahlmeter
- ‘Pre-emptive culturing’ will improve the chance of ‘getting it right’ when empirical therapy of urinary tract infections fails
J. Antimicrob. Chemother. 2009. 64:227-228.[Abstract] [Full Text] [PDF]
- Stephan Ludwig
- Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy
J. Antimicrob. Chemother. 2009. 64:1-4.[Abstract] [Full Text] [PDF]
- Kay Seden, David Back, and Saye Khoo
- Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable
J. Antimicrob. Chemother. 2009. 64:5-8.[Abstract] [Full Text] [PDF]
- Linos Vandekerckhove, Chris Verhofstede, and Dirk Vogelaers
- Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients
J. Antimicrob. Chemother. 2009. 63:1087-1096.[Abstract] [Full Text] [PDF]
- Roger Finch and Mike Sharland
- 18 November and beyond: observations on the EU Antibiotic Awareness Day
J. Antimicrob. Chemother. 2009. 63:633-635.[Abstract] [Full Text] [PDF]
- Brian Wells Pence
- The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS
J. Antimicrob. Chemother. 2009. 63:636-640.[Abstract] [Full Text] [PDF]
- Neil Woodford, David W. Wareham, and on behalf of the UK Antibacterial Antisense Study Group
- Tackling antibiotic resistance: a dose of common antisense?
J. Antimicrob. Chemother. 2009. 63:225-229.[Abstract] [Full Text] [PDF]
- Timothy Edgar, Stephanie D. Boyd, and Megan J. Palame
- Sustainability for behaviour change in the fight against antibiotic resistance: a social marketing framework
J. Antimicrob. Chemother. 2009. 63:230-237.[Abstract] [Full Text] [PDF]
- J. M. Blondeau
- What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?
J. Antimicrob. Chemother. 2009. 63:238-242.[Abstract] [Full Text] [PDF]
- David M. Livermore and Paul M. Tulkens
- Temocillin revived
J. Antimicrob. Chemother. 2009. 63:243-245.[Abstract] [Full Text] [PDF]
- Christian G. Giske, Arnfinn S. Sundsfjord, Gunnar Kahlmeter, Neil Woodford, Patrice Nordmann, David L. Paterson, Rafael Canton, and Timothy R. Walsh
- Redefining extended-spectrum β-lactamases: balancing science and clinical need
J. Antimicrob. Chemother. 2009. 63:1-4.[Abstract] [Full Text] [PDF]
- G. Gopal Rao and Mehool Patel
- Urinary tract infection in hospitalized elderly patients in the United Kingdom: the importance of making an accurate diagnosis in the post broad-spectrum antibiotic era
J. Antimicrob. Chemother. 2009. 63:5-6.[Abstract] [Full Text] [PDF]
- Matthew D. Marsden and Jerome A. Zack
- Eradication of HIV: current challenges and new directions
J. Antimicrob. Chemother. 2009. 63:7-10.[Abstract] [Full Text] [PDF]
- Tzu-Chun Chen, Kuo-Feng Weng, Shih-Cheng Chang, Jing-Yi Lin, Peng-Nien Huang, and Shin-Ru Shih
- Development of antiviral agents for enteroviruses
J. Antimicrob. Chemother. 2008. 62:1169-1173.[Abstract] [Full Text] [PDF]
- Cliodna A. M. McNulty and Alan P. Johnson
- The European Antibiotic Awareness Day
J. Antimicrob. Chemother. 2008. 62:853-854.[Abstract] [Full Text] [PDF]
- Rachel Hilton and C. Y. William Tong
- Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation
J. Antimicrob. Chemother. 2008. 62:855-859.[Abstract] [Full Text] [PDF]
- Johannes Wiegand, Katja Deterding, Markus Cornberg, and Heiner Wedemeyer
- Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon
J. Antimicrob. Chemother. 2008. 62:860-865.[Abstract] [Full Text] [PDF]
- David Richard Phillips and Phillip Hay
- Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy
J. Antimicrob. Chemother. 2008. 62:866-871.[Abstract] [Full Text] [PDF]
- Anna Maria Geretti
- Shifting paradigms: the resistance profile of etravirine
J. Antimicrob. Chemother. 2008. 62:643-647.[Abstract] [Full Text] [PDF]
- S. Harbarth and M. H. Samore
- Interventions to control MRSA: high time for time-series analysis?
J. Antimicrob. Chemother. 2008. 62:431-433.[Abstract] [Full Text] [PDF]
- Xilin Zhao and Karl Drlica
- A unified anti-mutant dosing strategy
J. Antimicrob. Chemother. 2008. 62:434-436.[Abstract] [Full Text] [PDF]
- Samson S. Y. Wong and Kwok-Yung Yuen
- The management of coronavirus infections with particular reference to SARS
J. Antimicrob. Chemother. 2008. 62:437-441.[Abstract] [Full Text] [PDF]
- Hong Zhang
- Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza
J. Antimicrob. Chemother. 2008. 62:219-223.[Abstract] [Full Text] [PDF]
- Nidhi A. Singh and Nancy Reau
- Management of hepatitis B virus
J. Antimicrob. Chemother. 2008. 62:224-228.[Abstract] [Full Text] [PDF]
- Vincent Soriano, Alan S. Perelson, and Fabien Zoulim
- Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
J. Antimicrob. Chemother. 2008. 62:1-4.[Abstract] [Full Text] [PDF]
- Linos Vandekerckhove, Chris Verhofstede, and Dirk Vogelaers
- Maraviroc: integration of a new antiretroviral drug class into clinical practice
J. Antimicrob. Chemother. 2008. 61:1187-1190.[Abstract] [Full Text] [PDF]
- Benedicte Roquebert and Anne-Genevieve Marcelin
- The involvement of HIV-1 RNAse H in resistance to nucleoside analogues
J. Antimicrob. Chemother. 2008. 61:973-975.[Abstract] [Full Text] [PDF]
- I. M. Gould
- Antibiotic policies to control hospital-acquired infection
J. Antimicrob. Chemother. 2008. 61:763-765.[Abstract] [Full Text] [PDF]
- Julie Sheldon and Vincent Soriano
- Hepatitis B virus escape mutants induced by antiviral therapy
J. Antimicrob. Chemother. 2008. 61:766-768.[Abstract] [Full Text] [PDF]
- Robert W. Burgoyne and Darrell H. S. Tan
- Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
J. Antimicrob. Chemother. 2008. 61:469-473.[Abstract] [Full Text] [PDF]
- Neil Woodford
- Successful, multiresistant bacterial clones
J. Antimicrob. Chemother. 2008. 61:233-234.[Abstract] [Full Text] [PDF]
- Johan W. Mouton, Ursula Theuretzbacher, William A. Craig, Paul M. Tulkens, Hartmut Derendorf, and Otto Cars
- Tissue concentrations: do we ever learn?
J. Antimicrob. Chemother. 2008. 61:235-237.[Abstract] [Full Text] [PDF]
- Katherine Samaras
- Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
J. Antimicrob. Chemother. 2008. 61:238-245.[Abstract] [Full Text] [PDF]
- B. Cherie Millar, Bernard D. Prendergast, and John E. Moore
- Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis
J. Antimicrob. Chemother. 2008. 61:1-7.[Abstract] [Full Text] [PDF]
- Caroline Foster and Hermione Lyall
- HIV and mitochondrial toxicity in children
J. Antimicrob. Chemother. 2008. 61:8-12.[Abstract] [Full Text] [PDF]
- Bonaventura Clotet
- Once-daily dosing of nevirapine in HAART
J. Antimicrob. Chemother. 2008. 61:13-16.[Abstract] [Full Text] [PDF]
- Pierre-Louis Toutain, Alain Bousquet-Melou, and Marilyn Martinez
- AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?
J. Antimicrob. Chemother. 2007. 60:1185-1188.[Abstract] [Full Text] [PDF]
- Nicola Price and Elizabeth H. Boxall
- Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression
J. Antimicrob. Chemother. 2007. 60:1189-1192.[Abstract] [Full Text] [PDF]
- Leonard Leibovici and Mical Paul
- Aminoglycoside/ß-lactam combinations in clinical practice
J. Antimicrob. Chemother. 2007. 60:911-912.[Abstract] [Full Text] [PDF]
- Robert G. Masterton and Michele Caldwell
- Improving practice—the Hospital Pharmacy Initiative revisited
J. Antimicrob. Chemother. 2007. 60:709-711.[Abstract] [Full Text] [PDF]
- Jonathan Cooke, Peter Davey, Hayley Wickens, Ann Jacklin, Conor Jamieson, Ysobel Gourlay, Kieran Hand, and Sally Wellsteed
- Improving practice—working together to improve the use of antimicrobials
J. Antimicrob. Chemother. 2007. 60:712-714.[Abstract] [Full Text] [PDF]
- Hanneke K. A. Knaapen and Pilar Barrera
- Therapy for Whipple's disease
J. Antimicrob. Chemother. 2007. 60:457-458.[Abstract] [Full Text] [PDF]
- Darius Armstrong-James
- Invasive Candida species infection: the importance of adequate empirical antifungal therapy
J. Antimicrob. Chemother. 2007. 60:459-460.[Abstract] [Full Text] [PDF]
- Nicolai Lohse, Ann-Brit Eg Hansen, Jan Gerstoft, and Niels Obel
- Improved survival in HIV-infected persons: consequences and perspectives
J. Antimicrob. Chemother. 2007. 60:461-463.[Abstract] [Full Text] [PDF]
- Guangbi Yao
- Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China
J. Antimicrob. Chemother. 2007. 60:201-205.[Abstract] [Full Text] [PDF]
- Carmen Y. Lim and Kris V. Kowdley
- Optimal duration of therapy in HBV-related cirrhosis
J. Antimicrob. Chemother. 2007. 60:2-6.[Abstract] [Full Text] [PDF]
- Sebastian G. B. Amyes, Fiona M. Walsh, and John S. Bradley
- Best in class: a good principle for antibiotic usage to limit resistance development?
J. Antimicrob. Chemother. 2007. 59:825-826.[Abstract] [Full Text] [PDF]
- William E. Delaney IV
- Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil
J. Antimicrob. Chemother. 2007. 59:827-832.[Abstract] [Full Text] [PDF]
- Ian Chopra
- The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?
J. Antimicrob. Chemother. 2007. 59:587-590.[Abstract] [Full Text] [PDF]
- Andrew Lucas, David Nolan, and Simon Mallal
- HLA-B*5701 screening for susceptibility to abacavir hypersensitivity
J. Antimicrob. Chemother. 2007. 59:591-593.[Abstract] [Full Text] [PDF]
- F. Goldstein
- The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus
J. Antimicrob. Chemother. 2007. 59:1-4.[Abstract] [Full Text] [PDF]
- Peter Davey
- The potential role of computerized decision support systems to improve empirical antibiotic prescribing
J. Antimicrob. Chemother. 2006. 58:1105-1106.[Abstract] [Full Text] [PDF]
- Jane Democratis, Manish Pareek, and Iain Stephenson
- Use of neuraminidase inhibitors to combat pandemic influenza
J. Antimicrob. Chemother. 2006. 58:911-915.[Abstract] [Full Text] [PDF]
- Y. Horsmans
- Interferon-induced depression in chronic hepatitis C
J. Antimicrob. Chemother. 2006. 58:711-713.[Abstract] [Full Text] [PDF]
- Vivienne Weston and Gerald Coakley
- Guideline for the management of the hot swollen joint in adults with a particular focus on septic arthritis
J. Antimicrob. Chemother. 2006. 58:492-493.[Abstract] [Full Text] [PDF]
- D. A. Mitchison
- Clinical development of anti-tuberculosis drugs
J. Antimicrob. Chemother. 2006. 58:494-495.[Abstract] [Full Text] [PDF]
- Sumita Verma
- HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
J. Antimicrob. Chemother. 2006. 58:496-501.[Abstract] [Full Text] [PDF]
- Marco Bongiovanni, Maddalena Casana, Camilla Tincati, and Antonella d'Arminio Monforte
- Treatment interruptions in HIV-infected subjects
J. Antimicrob. Chemother. 2006. 58:502-505.[Abstract] [Full Text] [PDF]
- Mauro Schechter and Suely Hiromi Tuboi
- Discordant immunological and virological responses to antiretroviral therapy
J. Antimicrob. Chemother. 2006. 58:506-510.[Abstract] [Full Text] [PDF]
- Eugenia Negredo, Anna Bonjoch, and Bonaventura Clotet
- Benefits and concerns of simplification strategies in HIV-infected patients
J. Antimicrob. Chemother. 2006. 58:235-242.[Abstract] [Full Text] [PDF]
- Mark A. Toleman, Peter M. Bennett, and Timothy R. Walsh
- Common regions e.g. orf513 and antibiotic resistance: IS91-like elements evolving complex class 1 integrons
J. Antimicrob. Chemother. 2006. 58:1-6.[Abstract] [Full Text] [PDF]
- Diego Rincon, Cristina Ripoll, Maria Vega Catalina, Magdalena Salcedo, and Rafael Banares
- Does interferon improve portal hypertension?
J. Antimicrob. Chemother. 2006. 58:7-12.[Abstract] [Full Text] [PDF]
- Richard Wise
- Antimicrobial resistance: paradox, actions and economics
J. Antimicrob. Chemother. 2006. 57:1024-1025.[Abstract] [Full Text] [PDF]
- Matthew J. Ellington and Neil Woodford
- Fluoroquinolone resistance and plasmid addiction systems: self-imposed selection pressure?
J. Antimicrob. Chemother. 2006. 57:1026-1029.[Abstract] [Full Text] [PDF]
- Melissa K. Osborn and Anna S. F. Lok
- Antiviral options for the treatment of chronic hepatitis B
J. Antimicrob. Chemother. 2006. 57:1030-1034.[Abstract] [Full Text] [PDF]
- Patricia K. Lee, Tara L. Kieffer, Robert F. Siliciano, and Richard E. Nettles
- HIV-1 viral load blips are of limited clinical significance
J. Antimicrob. Chemother. 2006. 57:803-805.[Abstract] [Full Text] [PDF]
- Pablo Barreiro and Vincent Soriano
- Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
J. Antimicrob. Chemother. 2006. 57:806-809.[Abstract] [Full Text] [PDF]
- Flavia B. Lillo and Caterina Uberti-Foppa
- Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women
J. Antimicrob. Chemother. 2006. 57:810-814.[Abstract] [Full Text] [PDF]
- Vincent Soriano, Pablo Barreiro, and Marina Nunez
- Management of chronic hepatitis B and C in HIV-coinfected patients
J. Antimicrob. Chemother. 2006. 57:815-818.[Abstract] [Full Text] [PDF]
- S. F. Stone, P. Price, and M. A. French
- Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease
J. Antimicrob. Chemother. 2006. 57:585-588.[Abstract] [Full Text] [PDF]
- R. Scott McClelland and Jared M. Baeten
- Reducing HIV-1 transmission through prevention strategies targeting HIV-1-seropositive individuals
J. Antimicrob. Chemother. 2006. 57:163-166.[Abstract] [Full Text] [PDF]
- Samuel A. Shelburne, Martin Montes, and Richard J. Hamill
- Immune reconstitution inflammatory syndrome: more answers, more questions
J. Antimicrob. Chemother. 2006. 57:167-170.[Abstract] [Full Text] [PDF]
- Susan Brown and Sebastian Amyes
- OXA ß-lactamases in Acinetobacter: the story so far
J. Antimicrob. Chemother. 2006. 57:1-3.[Abstract] [Full Text] [PDF]
- Sophie Grabar, Laurence Weiss, and Dominique Costagliola
- HIV infection in older patients in the HAART era
J. Antimicrob. Chemother. 2006. 57:4-7.[Abstract] [Full Text] [PDF]
- Robert G. Gish
- Treating HCV with ribavirin analogues and ribavirin-like molecules
J. Antimicrob. Chemother. 2006. 57:8-13.[Abstract] [Full Text] [PDF]
- Norbert Brau
- Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy
J. Antimicrob. Chemother. 2005. 56:991-995.[Abstract] [Full Text] [PDF]
- S. F. FitzGerald, C. Kelly, and H. Humphreys
- Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus
J. Antimicrob. Chemother. 2005. 56:996-999.[Abstract] [Full Text] [PDF]
- Ronald B. Turner and J. Owen Hendley
- Virucidal hand treatments for prevention of rhinovirus infection
J. Antimicrob. Chemother. 2005. 56:805-807.[Abstract] [Full Text] [PDF]
- David M. Livermore
- Tigecycline: what is it, and where should it be used?
J. Antimicrob. Chemother. 2005. 56:611-614.[Abstract] [Full Text] [PDF]
- S. Mauss and J. K. Rockstroh
- HCV/HIV-coinfection—is there a state of the art after APRICOT and RIBAVIC?
J. Antimicrob. Chemother. 2005. 56:615-618.[Abstract] [Full Text] [PDF]
- Tamiko Hisanaga, Daryl J. Hoban, and George G. Zhanel
- Mechanisms of resistance to telithromycin in Streptococcus pneumoniae
J. Antimicrob. Chemother. 2005. 56:447-450.[Abstract] [Full Text] [PDF]
- Pentti Huovinen
- Mathematical model—tell us the future!
J. Antimicrob. Chemother. 2005. 56:257-258.[Abstract] [Full Text] [PDF]
- Neil Woodford and Arnfinn Sundsfjord
- Molecular detection of antibiotic resistance: when and where?
J. Antimicrob. Chemother. 2005. 56:259-261.[Abstract] [Full Text] [PDF]
- Catherine Yates and Sebastian Amyes
- Extended-spectrum ß-lactamases in non-typhoidal Salmonella spp. isolated in the UK are now a reality: why the late arrival?
J. Antimicrob. Chemother. 2005. 56:262-264.[Abstract] [Full Text] [PDF]
- J. Gerardo Garcia-Lerma
- Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons
J. Antimicrob. Chemother. 2005. 56:265-269.[Abstract] [Full Text] [PDF]
- Kurt Vermeire and Dominique Schols
- Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs
J. Antimicrob. Chemother. 2005. 56:270-272.[Abstract] [Full Text] [PDF]
- Susan S. Kaplan and Charles B. Hicks
- Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection
J. Antimicrob. Chemother. 2005. 56:273-276.[Abstract] [Full Text] [PDF]
- Edward Gershburg and Joseph S. Pagano
- Epstein–Barr virus infections: prospects for treatment
J. Antimicrob. Chemother. 2005. 56:277-281.[Abstract] [Full Text] [PDF]
- Alan Winston and Marta Boffito
- The management of HIV-1 protease inhibitor pharmacokinetic interactions
J. Antimicrob. Chemother. 2005. 56:1-5.[Abstract] [Full Text] [PDF]
- Ana Milinkovic and Esteban Martinez
- Current perspectives on HIV-associated lipodystrophy syndrome
J. Antimicrob. Chemother. 2005. 56:6-9.[Abstract] [Full Text] [PDF]
- Robert W. Shafer and Jonathan M. Schapiro
- Drug resistance and antiretroviral drug development
J. Antimicrob. Chemother. 2005. 55:817-820.[Abstract] [Full Text] [PDF]
- Franco Maggiolo, Diego Ripamonti, and Fredy Suter
- Switch strategies in patients on effective HAART
J. Antimicrob. Chemother. 2005. 55:821-823.[Abstract] [Full Text] [PDF]
- Angel Luis Ballesteros, Daniel Fuster, Ramon Planas, Bonaventura Clotet, and Cristina Tural
- Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients
J. Antimicrob. Chemother. 2005. 55:824-827.[Abstract] [Full Text] [PDF]
- Ramazan Idilman
- Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy
J. Antimicrob. Chemother. 2005. 55:828-831.[Abstract] [Full Text] [PDF]
- Johan W. Mouton, Michael N. Dudley, Otto Cars, Hartmut Derendorf, and George L. Drusano
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
J. Antimicrob. Chemother. 2005. 55:601-607.[Abstract] [Full Text] [PDF]
- Fabien Zoulim
- Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models
J. Antimicrob. Chemother. 2005. 55:608-611.[Abstract] [Full Text] [PDF]
- Allison Martin and Patrick W. G. Mallon
- Therapeutic approaches to combating lipoatrophy: do they work?
J. Antimicrob. Chemother. 2005. 55:612-615.[Abstract] [Full Text] [PDF]
- Giulia Marchetti, Fabio Franzetti, and Andrea Gori
- Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
J. Antimicrob. Chemother. 2005. 55:401-409.[Abstract] [Full Text] [PDF]
- Ann Noe, Jean Plum, and Chris Verhofstede
- The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance
J. Antimicrob. Chemother. 2005. 55:410-412.[Abstract] [Full Text] [PDF]
- Gregory M. Lucas
- Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven
J. Antimicrob. Chemother. 2005. 55:413-416.[Abstract] [Full Text] [PDF]
- Juan A. Pineda and Juan Macias
- Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy
J. Antimicrob. Chemother. 2005. 55:417-419.[Abstract] [Full Text] [PDF]
- Marla J. Keller, Ana Tuyama, Maria Josefina Carlucci, and Betsy C. Herold
- Topical microbicides for the prevention of genital herpes infection
J. Antimicrob. Chemother. 2005. 55:420-423.[Abstract] [Full Text] [PDF]
- Judith N. Steenbergen, Jeff Alder, Grace M. Thorne, and Francis P. Tally
- Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
J. Antimicrob. Chemother. 2005. 55:283-288.[Abstract] [Full Text] [PDF]
- Christopher Cianci, Nicholas Meanwell, and Mark Krystal
- Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor
J. Antimicrob. Chemother. 2005. 55:289-292.[Abstract] [Full Text] [PDF]
- Jan Balzarini, Miguel Stevens, Erik De Clercq, Dominique Schols, and Christophe Pannecouque
- Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action
J. Antimicrob. Chemother. 2005. 55:135-138.[Abstract] [Full Text] [PDF]
- Norio Akuta and Hiromitsu Kumada
- Influence of hepatitis B virus genotypes on the response to antiviral therapies
J. Antimicrob. Chemother. 2005. 55:139-142.[Abstract] [Full Text] [PDF]
- Robert G. Masterton
- Antibiotic cycling: more than it might seem?
J. Antimicrob. Chemother. 2005. 55:1-5.[Abstract] [Full Text] [PDF]
- Chien-Ching Hung and Shan-Chwen Chang
- Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections
J. Antimicrob. Chemother. 2004. 54:849-853.[Abstract] [Full Text] [PDF]
- Daniel K. Benjamin Jr, Steven Hirschfeld, Coleen K. Cunningham, and Ross E. McKinney Jr
- Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials
J. Antimicrob. Chemother. 2004. 54:701-703.[Abstract] [Full Text] [PDF]
- Javier Rojo and Rafael Delgado
- Glycodendritic structures: promising new antiviral drugs
J. Antimicrob. Chemother. 2004. 54:579-581.[Abstract] [Full Text] [PDF]
- Kathryn L. Springer and Adriana Weinberg
- Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity
J. Antimicrob. Chemother. 2004. 54:582-586.[Abstract] [Full Text] [PDF]
- T. M. A. Weller and C. E. Jamieson
- The expanding role of the antibiotic pharmacist
J. Antimicrob. Chemother. 2004. 54:295-298.[Abstract] [Full Text] [PDF]
- Philip J. Budge and Barney S. Graham
- Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses
J. Antimicrob. Chemother. 2004. 54:299-302.[Abstract] [Full Text] [PDF]
- Heiner C. Bucher, James Young, and Manuel Battegay
- Protease inhibitor-sparing simplified maintenance therapy: a need for perspective
J. Antimicrob. Chemother. 2004. 54:303-305.[Abstract] [Full Text] [PDF]
- Mike Bray and Chad J. Roy
- Antiviral prophylaxis of smallpox
J. Antimicrob. Chemother. 2004. 54:1-5.[Abstract] [Full Text] [PDF]
- Janet D. Siliciano and Robert F. Siliciano
- A long-term latent reservoir for HIV-1: discovery and clinical implications
J. Antimicrob. Chemother. 2004. 54:6-9.[Abstract] [Full Text] [PDF]
- Amanda Mocroft and Jens D. Lundgren
- Starting highly active antiretroviral therapy: why, when and response to HAART
J. Antimicrob. Chemother. 2004. 54:10-13.[Abstract] [Full Text] [PDF]
- Robert T. Sarisky
- Non-nucleoside inhibitors of the HCV polymerase
J. Antimicrob. Chemother. 2004. 54:14-16.[Abstract] [Full Text] [PDF]
- Norbert Hubert Gruener, Maria-Christina Jung, and Carl Albrecht Schirren
- Recurrent hepatitis C virus infection after liver transplantation: natural course, therapeutic approach and possible mechanisms of viral control
J. Antimicrob. Chemother. 2004. 54:17-20.[Abstract] [Full Text] [PDF]
- Golo Ahlenstiel, Rainer P. Woitas, Jurgen Rockstroh, and Ulrich Spengler
- CC-chemokine receptor 5 (CCR5) in hepatitis C—at the crossroads of the antiviral immune response?
J. Antimicrob. Chemother. 2004. 53:895-898.[Abstract] [Full Text] [PDF]
- Conan MacDougall and B. Joseph Guglielmo
- Pharmacokinetics of valaciclovir
J. Antimicrob. Chemother. 2004. 53:899-901.[Abstract] [Full Text] [PDF]
- Lance R. Peterson and Axel Dalhoff
- Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing?
J. Antimicrob. Chemother. 2004. 53:902-905.[Abstract] [Full Text] [PDF]
- A. D. Russell
- Whither triclosan?
J. Antimicrob. Chemother. 2004. 53:693-695.[Abstract] [Full Text] [PDF]
- David R. Bangsberg, Andrew R. Moss, and Steven G. Deeks
- Paradoxes of adherence and drug resistance to HIV antiretroviral therapy
J. Antimicrob. Chemother. 2004. 53:696-699.[Abstract] [Full Text] [PDF]
- J. K. Rockstroh and S. Mauss
- Clinical perspective of fusion inhibitors for treatment of HIV
J. Antimicrob. Chemother. 2004. 53:700-702.[Abstract] [Full Text] [PDF]
- Spotswood L. Spruance and Joanne Hill
- Clinical significance of antiviral therapy for episodic treatment of herpes labialis: exploratory analyses of the combined data from two valaciclovir trials
J. Antimicrob. Chemother. 2004. 53:703-707.[Abstract] [Full Text] [PDF]
- Douglas D. Richman
- Benefits and limitations of testing for resistance to HIV drugs
J. Antimicrob. Chemother. 2004. 53:555-557.[Abstract] [Full Text] [PDF]
- Yazdan Yazdanpanah
- Costs associated with combination antiretroviral therapy in HIV-infected patients
J. Antimicrob. Chemother. 2004. 53:558-561.[Abstract] [Full Text] [PDF]
- Victor E. Buckwold
- Implications of finding synergic in vitro drug–drug interactions between interferon- and ribavirin for the treatment of hepatitis C virus
J. Antimicrob. Chemother. 2004. 53:413-414.[Abstract] [Full Text] [PDF]
- Emilio Fumero, Felipe Garcia, and J. M. Gatell
- Immunosuppressive drugs as an adjuvant to HIV treatment
J. Antimicrob. Chemother. 2004. 53:415-417.[Abstract] [Full Text] [PDF]
- Beverley C. Millar and John E. Moore
- Antibiotic prophylaxis, body piercing and infective endocarditis
J. Antimicrob. Chemother. 2004. 53:123-126.[Abstract] [Full Text] [PDF]
- Louis Bernard, Pierre Hoffmeyer, Mathieu Assal, Pierre Vaudaux, Jacques Schrenzel, and Daniel Lew
- Trends in the treatment of orthopaedic prosthetic infections
J. Antimicrob. Chemother. 2004. 53:127-129.[Abstract] [Full Text] [PDF]
- Ben de Pauw
- Preventative use of antifungal drugs in patients treated for cancer
J. Antimicrob. Chemother. 2004. 53:130-132.[Abstract] [Full Text] [PDF]
- John Oxford, Shobana Balasingam, and Rob Lambkin
- A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
J. Antimicrob. Chemother. 2004. 53:133-136.[Abstract] [Full Text] [PDF]
- Hans-Ulrich Bernard
- Established and potential strategies against papillomavirus infections
J. Antimicrob. Chemother. 2004. 53:137-139.[Abstract] [Full Text] [PDF]
- Elisabeta Vergu, Alain Mallet, and Jean-Louis Golmard
- Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection
J. Antimicrob. Chemother. 2004. 53:140-143.[Abstract] [Full Text] [PDF]
- Justin Stebbing, Philip Savage, Steve Patterson, and Brian Gazzard
- All for CD91 and CD91 for all
J. Antimicrob. Chemother. 2004. 53:1-3.[Abstract] [Full Text] [PDF]
- Robert K. Zeldin and Richard A. Petruschke
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
J. Antimicrob. Chemother. 2004. 53:4-9.[Abstract] [Full Text] [PDF]
- Leonardo Calza, Roberto Manfredi, and Francesco Chiodo
- Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients
J. Antimicrob. Chemother. 2004. 53:10-14.[Abstract] [Full Text] [PDF]
- Peter Ferenci
- Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
J. Antimicrob. Chemother. 2004. 53:15-18.[Abstract] [Full Text] [PDF]
- Keisuke Hino and Kiwamu Okita
- Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C
J. Antimicrob. Chemother. 2004. 53:19-22.[Abstract] [Full Text] [PDF]
- Fang Fang and Mang Yu
- Viral receptor blockage by multivalent recombinant antibody fusion proteins: inhibiting human rhinovirus (HRV) infection with CFY196
J. Antimicrob. Chemother. 2004. 53:23-25.[Abstract] [Full Text] [PDF]
- John Turnidge
- Antibiotic use in animals—prejudices, perceptions and realities
J. Antimicrob. Chemother. 2004. 53:26-27.[Abstract] [Full Text] [PDF]
- Shirit Einav and Jeffrey S. Glenn
- Prenylation inhibitors: a novel class of antiviral agents
J. Antimicrob. Chemother. 2003. 52:883-886.[Abstract] [Full Text] [PDF]
- Melissa M. Herbst and Richard B. Pyles
- Immunostimulatory CpG treatment for genital HSV-2 infections
J. Antimicrob. Chemother. 2003. 52:887-889.[Full Text] [PDF]
- John P. Moore and Robin J. Shattock
- Preventing HIV-1 sexual transmission—not sexy enough science, or no benefit to the bottom line?
J. Antimicrob. Chemother. 2003. 52:890-892.[Full Text] [PDF]
- Johannes A. Bogaards and Jaap Goudsmit
- Meeting the immense need for HAART in resource-poor settings
J. Antimicrob. Chemother. 2003. 52:743-746.[Full Text] [PDF]
- Anthony Kebba
- Antiretroviral therapy in sub-Saharan Africa: myth or reality?
J. Antimicrob. Chemother. 2003. 52:747-749.[Full Text] [PDF]
- Pramod M. Shah and Robin D. Isaacs
- Ertapenem, the first of a new group of carbapenems
J. Antimicrob. Chemother. 2003. 52:538-542.[Full Text] [PDF]
- Jim Zhen Wu, Chin-chung Lin, and Zhi Hong
- Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design
J. Antimicrob. Chemother. 2003. 52:543-546.[Full Text] [PDF]
- Nancy A. Jewell, Renxiang Chen, Raquel Raices, and Louis M. Mansky
- Nucleoside reverse transcriptase inhibitors and HIV mutagenesis
J. Antimicrob. Chemother. 2003. 52:547-550.[Full Text] [PDF]
- A. Fraternale, A. Casabianca, L. Rossi, L. Chiarantini, G. F. Schiavano, A. T. Palamara, E. Garaci, and M. Magnani
- Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections
J. Antimicrob. Chemother. 2003. 52:551-554.[Full Text] [PDF]
- Denise Paulsen, Robert Elston, Wendy Snowden, Margaret Tisdale, and Lisa Ross
- Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects
J. Antimicrob. Chemother. 2003. 52:319-323.[Full Text] [PDF]
- Gunnar Kahlmeter, Derek F. J. Brown, Fred W. Goldstein, Alasdair P. MacGowan, Johan W. Mouton, Anders Osterlund, Arne Rodloff, Martin Steinbakk, Pavla Urbaskova, and Alkiviadis Vatopoulos
- European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
J. Antimicrob. Chemother. 2003. 52:145-148.[Full Text] [PDF]
- Shiou-Hwei Yeh, Ding-Shinn Chen, and Pei-Jer Chen
- A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis
J. Antimicrob. Chemother. 2003. 52:149-151.[Full Text] [PDF]
- Michelle Swanson-Mungerson, Masato Ikeda, Lori Lev, Richard Longnecker, and Toni Portis
- Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein–Barr virus (EBV)-associated diseases
J. Antimicrob. Chemother. 2003. 52:152-154.[Full Text] [PDF]
- Rafael de la Rosa and Manuel Leal
- Thymic involvement in recovery of immunity among HIV-infected adults on highly active antiretroviral therapy
J. Antimicrob. Chemother. 2003. 52:155-158.[Full Text] [PDF]
- Nancy D. Hanson
- AmpC ß-lactamases: what do we need to know for the future?
J. Antimicrob. Chemother. 2003. 52:2-4.[Full Text] [PDF]
- K. Kummerer
- Significance of antibiotics in the environment
J. Antimicrob. Chemother. 2003. 52:5-7.[Full Text] [PDF]
- Noboru Uchide and Kunio Ohyama
- Antiviral function of pyrrolidine dithiocarbamate against influenza virus: the inhibition of viral gene replication and transcription
J. Antimicrob. Chemother. 2003. 52:8-10.[Full Text] [PDF]
- Heather J. Smith, Kimberly A. Nichol, Daryl J. Hoban, and George G. Zhanel
- Stretching the mutant prevention concentration (MPC) beyond its limits
J. Antimicrob. Chemother. 2003. 51:1323-1325.[Full Text] [PDF]
- Beatrice Macchi, Emanuela Balestrieri, and Antonio Mastino
- Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro
J. Antimicrob. Chemother. 2003. 51:1327-1330.[Full Text] [PDF]
- F. Van Bambeke, Y. Glupczynski, P. Plesiat, J. C. Pechere, and P. M. Tulkens
- Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy
J. Antimicrob. Chemother. 2003. 51:1055-1065.[Full Text] [PDF]
- F. Van Bambeke, J.-M. Michot, and P. M. Tulkens
- Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics
J. Antimicrob. Chemother. 2003. 51:1067-1077.[Full Text] [PDF]
- Erik De Clercq
- New inhibitors of human cytomegalovirus (HCMV) on the horizon
J. Antimicrob. Chemother. 2003. 51:1079-1083.[Full Text] [PDF]
- Naohiro Kamiya
- The mechanisms of action of antivirals against hepatitis B virus infection
J. Antimicrob. Chemother. 2003. 51:1085-1089.[Full Text] [PDF]
- Catherine L. Cherry and Steven L. Wesselingh
- Nucleoside analogues and HIV: the combined cost to mitochondria
J. Antimicrob. Chemother. 2003. 51:1091-1093.[Full Text] [PDF]
- Justin Stebbing, Simon Portsmouth, and Brian Gazzard
- How does HAART lead to the resolution of Kaposi’s sarcoma?
J. Antimicrob. Chemother. 2003. 51:1095-1098.[Full Text] [PDF]
- Marla J. Keller, Mary E. Klotman, and Betsy C. Herold
- Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus
J. Antimicrob. Chemother. 2003. 51:1099-1102.[Full Text] [PDF]
- Dilip Nathwani
- From evidence-based guideline methodology to quality of care standards
J. Antimicrob. Chemother. 2003. 51:1103-1107.[Full Text] [PDF]
- Scott D. Mills
- The role of genomics in antimicrobial discovery
J. Antimicrob. Chemother. 2003. 51:749-752.[Full Text] [PDF]
- Glen A. Coburn and Bryan R. Cullen
- siRNAs: a new wave of RNA-based therapeutics
J. Antimicrob. Chemother. 2003. 51:753-756.[Full Text] [PDF]
- Gabriela Stiegler and Hermann Katinger
- Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection
J. Antimicrob. Chemother. 2003. 51:757-759.[Full Text] [PDF]
- Man-Fung Yuen and Ching-Lung Lai
- Current and future antiviral agents for chronic hepatitis B
J. Antimicrob. Chemother. 2003. 51:481-485.[Full Text] [PDF]
- Samuel S. Lee and Ayman A. Abdo
- Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?
J. Antimicrob. Chemother. 2003. 51:487-491.[Full Text] [PDF]
- Patrick G. Hoggard and Andrew Owen
- The mechanisms that control intracellular penetration of the HIV protease inhibitors
J. Antimicrob. Chemother. 2003. 51:493-496.[Full Text] [PDF]
- Paolo Monini, Cecilia Sgadari, Giovanni Barillari, and Barbara Ensoli
- HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity
J. Antimicrob. Chemother. 2003. 51:207-211.[Full Text] [PDF]
- Graeme Moyle
- Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART
J. Antimicrob. Chemother. 2003. 51:213-217.[Full Text] [PDF]
- Damian J. McColl and Michael D. Miller
- The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1
J. Antimicrob. Chemother. 2003. 51:219-223.[Full Text] [PDF]
- Federico Pulido and Jose R. Arribas
- Treatment of advanced HIV infection
J. Antimicrob. Chemother. 2003. 51:225-227.[Full Text] [PDF]
- Christoph G. Lange and Michael M. Lederman
- Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection
J. Antimicrob. Chemother. 2003. 51:1-4.[Full Text] [PDF]
- George M. Bahr
- Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide
J. Antimicrob. Chemother. 2003. 51:5-8.[Full Text] [PDF]
- M. A. Webber and L. J. V. Piddock
- The importance of efflux pumps in bacterial antibiotic resistance
J. Antimicrob. Chemother. 2003. 51:9-11.[Full Text] [PDF]
- J. Gerardo Garcia-Lerma and Walid Heneine
- Rapid biochemical assays for phenotypic drug resistance testing of HIV-1
J. Antimicrob. Chemother. 2002. 50:771-774.[Full Text] [PDF]
- Gunnar Kahlmeter and Derek F. J. Brown
- Resistance surveillance studies—comparability of results and quality assurance of methods
J. Antimicrob. Chemother. 2002. 50:775-777.[Full Text] [PDF]
- Alan P. Johnson and Neil Woodford
- Glycopeptide-resistant Staphylococcus aureus
J. Antimicrob. Chemother. 2002. 50:621-623.[Full Text] [PDF]
- A. Sullivan and C. E. Nord
- Probiotics in human infections
J. Antimicrob. Chemother. 2002. 50:625-627.[Full Text] [PDF]
- Tuofu Zhu
- HIV-1 in peripheral blood monocytes: an underrated viral source
J. Antimicrob. Chemother. 2002. 50:309-311.[Full Text] [PDF]
- Pietro E. Varaldo
- Antimicrobial resistance and susceptibility testing: an evergreen topic
J. Antimicrob. Chemother. 2002. 50:1-4.[Full Text] [PDF]
- David W. Denning
- Echinocandins: a new class of antifungal
J. Antimicrob. Chemother. 2002. 49:889-891.[Full Text] [PDF]
- Heather J. Smith, Kimberly A. Nichol, Daryl J. Hoban, and George G. Zhanel
- Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
J. Antimicrob. Chemother. 2002. 49:893-895.[Full Text] [PDF]
- H. Lode and M. Allewelt
- Role of newer fluoroquinolones in lower respiratory tract infections
J. Antimicrob. Chemother. 2002. 49:709-712.[Full Text] [PDF]
- Richard Wise
- Antimicrobial resistance: priorities for action
J. Antimicrob. Chemother. 2002. 49:585-586.[Full Text] [PDF]
- Erwin M. Brown
- Guidelines for antibiotic usage in hospitals
J. Antimicrob. Chemother. 2002. 49:587-592.[Full Text] [PDF]
- Ethan Rubinstein and John Camm
- Cardiotoxicity of fluoroquinolones
J. Antimicrob. Chemother. 2002. 49:593-596.[Full Text] [PDF]
- A. D. Russell
- Mechanisms of antimicrobial action of antiseptics and disinfectants: an increasingly important area of investigation
J. Antimicrob. Chemother. 2002. 49:597-599.[Full Text] [PDF]
- William Bishai
- The in vivo–in vitro paradox in pneumococcal respiratory tract infections
J. Antimicrob. Chemother. 2002. 49:433-436.[Full Text] [PDF]
- Helen Giamarellou
- Prescribing guidelines for severe Pseudomonas infections
J. Antimicrob. Chemother. 2002. 49:229-233.[Full Text] [PDF]
- Niels Hoiby
- New antimicrobials in the management of cystic fibrosis
J. Antimicrob. Chemother. 2002. 49:235-238.[Full Text] [PDF]
- Georg Maschmeyer
- New antifungal agents—treatment standards are beginning to grow old
J. Antimicrob. Chemother. 2002. 49:239-241.[Full Text] [PDF]
- Deirdre Lewis
- Antimicrobial resistance surveillance: methods will depend on objectives
J. Antimicrob. Chemother. 2002. 49:3-5.[Full Text] [PDF]
- A. K. Morris and R. G. Masterton
- Antibiotic resistance surveillance: action for international studies
J. Antimicrob. Chemother. 2002. 49:7-10.[Full Text] [PDF]
- A. P. Fraise
- Biocide abuse and antimicrobial resistance—a cause for concern?
J. Antimicrob. Chemother. 2002. 49:11-12.[Full Text] [PDF]
- B. Chattopadhyay
- Newborns and gentamicin—how much and how often?
J. Antimicrob. Chemother. 2002. 49:13-16.[Full Text] [PDF]
- Caroline A. Sabin and Andrew N. Phillips
- Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies
J. Antimicrob. Chemother. 2001. 47:371-375.[Full Text] [PDF]
- David M. Livermore
- Of Pseudomonas, porins, pumps and carbapenems
J. Antimicrob. Chemother. 2001. 47:247-250.[Full Text] [PDF]
- Marc D. Cubbon and Robert G. Masterton
- New quinolones—a fresh answer to the pneumococcus
J. Antimicrob. Chemother. 2000. 46:869-872.[Full Text] [PDF]
- Elizabeth H. Price, John de Louvois, and M. Rella Workman
- Antibiotics for Salmonella meningitis in children
J. Antimicrob. Chemother. 2000. 46:653-655.[Full Text] [PDF]
- Francis P. Tally and Michael F. DeBruin
- Development of daptomycin for Gram-positive infections
J. Antimicrob. Chemother. 2000. 46:523-526.[Full Text] [PDF]
- David M. Livermore
- Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
J. Antimicrob. Chemother. 2000. 46:347-350.[Full Text] [PDF]
- Kurt G. Naber and Wolfgang Weidner
- Chronic prostatitis—an infectious disease?
J. Antimicrob. Chemother. 2000. 46:157-161.[Full Text] [PDF]
- Heike Brotz and Hans-Georg Sahl
- New insights into the mechanism of action of lantibiotics—diverse biological effects by binding to the same molecular target
J. Antimicrob. Chemother. 2000. 46:1-6.[Full Text] [PDF]
- E. John Threlfall
- Epidemic Salmonella typhimurium DT 104—a truly international multiresistant clone
J. Antimicrob. Chemother. 2000. 46:7-10.[Full Text] [PDF]
- Kenneth S. Thomson
- Minimizing quinolone resistance: are the new agents more or less likely to cause resistance?
J. Antimicrob. Chemother. 2000. 45:719-723.[Full Text] [PDF]
- S. Esposito
- Outpatient parenteral treatment of bacterial infections: the Italian model as an international trend?
J. Antimicrob. Chemother. 2000. 45:724-727.[Full Text] [PDF]
- Peter Ball
- Quinolone-induced QT interval prolongation: a not-so-unexpected class effect
J. Antimicrob. Chemother. 2000. 45:557-559.[Full Text] [PDF]
- Susan M. Drake
- NNRTIs—a new class of drugs for HIV
J. Antimicrob. Chemother. 2000. 45:417-420.[Full Text] [PDF]
- Issam Raad
- Management of intravascular catheter-related infections
J. Antimicrob. Chemother. 2000. 45:267-270.[Full Text] [PDF]
- M. Youle
- Is interruption of HIV therapy always harmful?
J. Antimicrob. Chemother. 2000. 45:137-138.[Full Text] [PDF]
- Jeffrey R. Edwards and Michael J. Betts
- Carbapenems: the pinnacle of the ß-lactam antibiotics or room for improvement?
J. Antimicrob. Chemother. 2000. 45:1-4.[Full Text] [PDF]
- S. Ragnar Norrby
- Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis
J. Antimicrob. Chemother. 2000. 45:5-7.[Full Text] [PDF]
- Ian Phillips
- The use of bacitracin as a growth promoter in animals produces no risk to human health
J. Antimicrob. Chemother. 1999. 44:725-728.[Full Text] [PDF]
- Kevin G. Kerr
- The prophylaxis of bacterial infections in neutropenic patients
J. Antimicrob. Chemother. 1999. 44:587-591.[Full Text] [PDF]
- Joanne M. Legg and Adrian J. Bint
- Will pneumococci put quinolones in their place?
J. Antimicrob. Chemother. 1999. 44:425-427.[Full Text] [PDF]
- Fred W. Goldstein
- Penicillin-resistant Streptococcus pneumoniae: selection by both ß-lactam and non-ß-lactam antibiotics
J. Antimicrob. Chemother. 1999. 44:141-144.[Full Text] [PDF]
- P. J. Cook
- Antimicrobial therapy for Chlamydia pneumoniae: its potential role in atherosclerosis and asthma
J. Antimicrob. Chemother. 1999. 44:145-148.[Full Text] [PDF]
- Guy W. Amsden
- Pneumococcal macrolide resistance—myth or reality?
J. Antimicrob. Chemother. 1999. 44:1-6.[Full Text] [PDF]
- Iain Stephenson and Karl G. Nicholson
- Chemotherapeutic control of influenza
J. Antimicrob. Chemother. 1999. 44:6-10.[Full Text] [PDF]
- Martin Dedicoat and Pradhib Venkatesan
- The treatment of Legionnaires' disease
J. Antimicrob. Chemother. 1999. 43:747-752.[Full Text] [PDF]
- Tom S. J. Elliott
- Role of antimicrobial central venous catheters for the prevention of associated infections
J. Antimicrob. Chemother. 1999. 43:441-446.[Full Text] [PDF]
- Omrum Uzun and Elias J. Anaissie
- Outpatient therapy for febrile neutropenia: who, when and how?
J. Antimicrob. Chemother. 1999. 43:317-320.[Full Text] [PDF]
- Lee Ann Thal and Marcus J. Zervos
- Occurrence and epidemiology of resistance to virginiamycin and streptogramins
J. Antimicrob. Chemother. 1999. 43:171-176.[Full Text] [PDF]
- Peter M. Bennett
- Integrons and gene cassettes: a genetic construction kit for bacteria
J. Antimicrob. Chemother. 1999. 43:1-4.[Full Text] [PDF]
- JL Martinez, A Alonso, JM Gomez-Gomez, and F Baquero
- Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
J. Antimicrob. Chemother. 1998. 42:683-688.[PDF]
- RG Finch, DI Pritchard, BW Bycroft, P Williams, and GS Stewart
- Quorum sensing: a novel target for anti-infective therapy
J. Antimicrob. Chemother. 1998. 42:569-571.[PDF]
- SG Amyes and RS Miles
- Extended-spectrum beta-lactamases: the role of inhibitors in therapy
J. Antimicrob. Chemother. 1998. 42:415-417.[PDF]
- AP Fraise
- Guidelines for the control of methicillin-resistant Staphylococcus aureus
J. Antimicrob. Chemother. 1998. 42:287-289.[PDF]
- RG Finch
- Antibiotic resistance
J. Antimicrob. Chemother. 1998. 42:125-128.[PDF]
- AF Goddard
- Getting to the route of Helicobacter pylori treatment
J. Antimicrob. Chemother. 1998. 42:1-3.[PDF]
- H Labischinski, K Ehlert, and B Berger-Bachi
- The targeting of factors necessary for expression of methicillin resistance in staphylococci
J. Antimicrob. Chemother. 1998. 41:581-584.[PDF]
- DJ Leaper
- Use of antibiotic prophylaxis in clean non-implant wounds
J. Antimicrob. Chemother. 1998. 41:501-504.[PDF]
- FR Falkiner
- The consequences of antibiotic use in horticulture
J. Antimicrob. Chemother. 1998. 41:429-431.[PDF]
- JP Burnie and RC Matthews
- The renaissance of antibody therapy
J. Antimicrob. Chemother. 1998. 41:319-322.[PDF]
- P Venkatesan
- Albendazole
J. Antimicrob. Chemother. 1998. 41:145-147.[PDF]
- RD Walker and C Thornsberry
- Decrease in antibiotic susceptibility or increase in resistance?
J. Antimicrob. Chemother. 1998. 41:1-4.[PDF]
- M Whitby
- Drug resistant Plasmodium vivax malaria
J. Antimicrob. Chemother. 1997. 40:749-752.[PDF]
- DW Denning
- Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
J. Antimicrob. Chemother. 1997. 40:611-614.[PDF]
- EM Brown
- Empirical antimicrobial therapy of mechanically ventilated patients with nosocomial pneumonia
J. Antimicrob. Chemother. 1997. 40:463-468.[PDF]
- R Booy and JS Kroll
- Is Haemophilus influenzae finished?
J. Antimicrob. Chemother. 1997. 40:149-153.[PDF]
- MH Nicolas-Chanoine
- Inhibitor-resistant beta-lactamases
J. Antimicrob. Chemother. 1997. 40:1-3.[PDF]
- DM Livermore
- Acquired carbapenemases
J. Antimicrob. Chemother. 1997. 39:673-676.[PDF]
- SA Locarnini and JE Newbold
- Chronic hepatitis B: the therapeutic challenge
J. Antimicrob. Chemother. 1997. 39:559-562.[PDF]
- D Nathwani, G Tillotson, and P Davey
- Sequential antimicrobial therapy--the role of quinolones
J. Antimicrob. Chemother. 1997. 39:441-446.[PDF]
- HM Taylor and JB Bingham
- Antibiotic prophylaxis for transrectal prostate biopsy
J. Antimicrob. Chemother. 1997. 39:115-117.[PDF]
- K Bush and G Jacoby
- Nomenclature of TEM beta-lactamases
J. Antimicrob. Chemother. 1997. 39:1-3.[PDF]
- GRAEME J. MOYLE and SIMON E. BARTON
- HIV-proteinase inhibitors in the management of HIV-infection
J. Antimicrob. Chemother. 1996. 38:921-925.[PDF]
- ADAM P FRAISE
- The treatment and control of vancomycin-resistant enterococci
J. Antimicrob. Chemother. 1996. 38:753-756.[PDF]
- CHRISTOPHER P. CONLON
- Outpatient intravenous antibiotic therapy
J. Antimicrob. Chemother. 1996. 38:557-559.[PDF]
- HILARY HUMPHREYS and THOMAS WALLEY
- Patient packs and the prescribing of antimicrobial agents
J. Antimicrob. Chemother. 1996. 38:329-331.[PDF]
- S. AKHTAR and J. J. ROSSI
- Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?
J. Antimicrob. Chemother. 1996. 38:159-165.[PDF]
- LAURA J. V. PIDDOCK
- Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy?
J. Antimicrob. Chemother. 1996. 38:1-3.[PDF]
- SARAH GANDER
- Bacterial biofllms: resistance to antimicrobial agents: J Anlimicrob Chemother 1996; 37: 1047–1050
J. Antimicrob. Chemother. 1996. 37:1047-1050.[PDF]
- ANDREW F. GODDARD and ROBERT P. H. LOGAN
- Antimicrobial resistance and Helicobacter pylori
J. Antimicrob. Chemother. 1996. 37:639-643.[PDF]
- JANE H. LANGFORD and SHALOM I. BENRIMOJ
- Clinical rationale for topical antimicrobial preparations
J. Antimicrob. Chemother. 1996. 37:399-402.[PDF]
- ROBERT WILSON, GLENN TILLOTSON, and PETER BALL
- Clinical studies in chronic bronchitis: a need for better definition and classification of severity
J. Antimicrob. Chemother. 1996. 37:205-208.[PDF]
- ALASDAIR MACGOWAN
- Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy?: J Antimicrob Chemother 1996; 37: 1–5
J. Antimicrob. Chemother. 1996. 37:1-5.[PDF]
- P. D. O. DAVIES
- Multiple drug resistant tuberculosis: centralized mycobacterial reference using molecular techniques can help: J Antimicrob Chemother 1996; 37: 5–6
J. Antimicrob. Chemother. 1996. 37:5-6.[PDF]
- A. M. SHIBL, J.-C. PECHERE, and M. A. RAMADAN
- Postantibiotic effect and host-bacteria interactions
J. Antimicrob. Chemother. 1995. 36:885-887.[PDF]
- P. PERITI
- Evolution of the bacterial dihydrofolate reductase inhibitors
J. Antimicrob. Chemother. 1995. 36:887-890.[PDF]
- ELIZABETH M. JOHNSON and DAVID W. WARNOCK
- Azole drug resistance in yeasts
J. Antimicrob. Chemother. 1995. 36:751-755.[PDF]
- D. GERAINT JAMES
- Treatment options for chronic hepatitis C infection
J. Antimicrob. Chemother. 1995. 36:591-593.[PDF]
- RON DAGAN
- Why should paediatric patients with serious infections be hospitalized?
J. Antimicrob. Chemother. 1995. 36:451-452.[PDF]
- N. J. SAUNDERS
- Vancomycin administration and monitoring reappraisal
J. Antimicrob. Chemother. 1995. 36:279-282.[PDF]
- A.P.R. WILSON
- Antibiotic prophylaxis and infection control measures in minimally invasive surgery
J. Antimicrob. Chemother. 1995. 36:1-5.[PDF]
- A. P. R. WILSON
- Treatment of infection caused by toxigenic and Bon-toxigenic strains of Corynebacterium diphtheriae
J. Antimicrob. Chemother. 1995. 35:717-720.[PDF]
- GEORGE R. BAILIE and GEORGE EISELE
- Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis
J. Antimicrob. Chemother. 1995. 35:563-567.[PDF]
- F. T. TALLY, G. A. ELLESTAD, and R. T. TESTA
- Glycylcyclines: a new generation of tetracyclines
J. Antimicrob. Chemother. 1995. 35:449-452.[PDF]
- A. W. SMITH
- Stationary phase induction in Escherichia coli—new targets for antimicrobial therapy?
J. Antimicrob. Chemother. 1995. 35:359-361.[PDF]
- M. A. VIVIANI
- Flucytosine—what is its future?
J. Antimicrob. Chemother. 1995. 35:241-244.[PDF]
- D. LIVINGSTONE, M. J. GILL, and R. WISE
- Mechanisms of resistance to the carbapenems
J. Antimicrob. Chemother. 1995. 35:1-5.[PDF]
- DAVIS S. REEVES
- Fosfomycin trometamol
J. Antimicrob. Chemother. 1994. 34:853-858.[PDF]
- B. RUF and J. SANDFORT
- Human microsporidiosis: J Antimicrob Chemother 1994, 34: 609–611
J. Antimicrob. Chemother. 1994. 34:609-611.[PDF]
- KEITH POOLE
- Bacterial multidrug resistance—emphasis on efflux mechanisms and Pseudomonas aeruginosa
J. Antimicrob. Chemother. 1994. 34:453-456.[PDF]
- PHILIPPA EASTERBROOK and MARTIN J. WOOD
- Leading article
J. Antimicrob. Chemother. 1994. 34:307-311.[PDF]
- K. P. KLUGMAN
- Management of antibiotic-resistant pneumococcal infections
J. Antimicrob. Chemother. 1994. 34:191-193.[PDF]
- Drug intolerance in HIV disease
J. Antimicrob. Chemother. 1994. 34:1-5.[PDF]
- LINDA C. NEW and RICHARD E. HOLLIMAN
- Toxoplasmosis and human immunodeficiency virus (HIV) disease
J. Antimicrob. Chemother. 1994. 33:1079-1082.[PDF]
- N. CLUMECK
- Antimicrobial prophylaxis in HIV-infected adults
J. Antimicrob. Chemother. 1994. 33:903-905.[PDF]
- A. KHWAJA and D. C. LINCH
- Haemopoietic growth factors in the treatment of infection in non-neutropenic patients
J. Antimicrob. Chemother. 1994. 33:679-683.[PDF]
- ROBERT WILSON and CHARLOTTE RAYNER
- Animal models of respiratory infection
J. Antimicrob. Chemother. 1994. 33:381-383.[PDF]
- IBRAHIM J. HASSAN
- Endophthalmitis—problems, progress and prospects
J. Antimicrob. Chemother. 1994. 33:383-386.[PDF]
- J. M. T. HAMILTON-MILLER
- Dual-action antibiotic hybrids
J. Antimicrob. Chemother. 1994. 33:197-200.[PDF]
- C. S. MCARDLE
- Oral prophylaxis in biliary tract surgery
J. Antimicrob. Chemother. 1994. 33:200-202.[PDF]
- J.J.S. SNELL
- Problems in susceptibility testings—findings of UK NEQAS for microbiology
J. Antimicrob. Chemother. 1994. 33:1-4.[PDF]
- R. C. READ and R. G. FINCH
- Prophylaxis after splenectomy: J Antimicrob Chemother 1994; 33: 4–6
J. Antimicrob. Chemother. 1994. 33:4-6.[PDF]
- JONATHAN WEBER
- The molecular basis of anti-retroviral therapy
J. Antimicrob. Chemother. 1993. 32:789-792.[PDF]
- A. P. R. WILSON, R. N. GRUNEBERG, and H. NEU
- Dosage recommendations for teicoplanin
J. Antimicrob. Chemother. 1993. 32:792-796.[PDF]
- DAVID FELMINGHAM
- Towards the ideal glycopeptide
J. Antimicrob. Chemother. 1993. 32:663-666.[PDF]
- R. J. HAY
- The prevention of invasive aspergillosis-a realistic goal?
J. Antimicrob. Chemother. 1993. 32:515-517.[PDF]
- I. CHOPRA
- The magainins: antimicrobial peptides with potential for topical application
J. Antimicrob. Chemother. 1993. 32:351-353.[PDF]
- CLAUDE CARBON and PAUL LEOPHONTE
- Management of community-acquired pneumonia
J. Antimicrob. Chemother. 1993. 32:1-3.[PDF]
- RUTH C. MATTHEWS
- Early diagnosis of systemic candidal infection
J. Antimicrob. Chemother. 1993. 31:809-812.[PDF]
- D. NATHWANI and M. J. WOOD
- The management of travellers' diarrhoea
J. Antimicrob. Chemother. 1993. 31:623-626.[PDF]
- R. F. HALLIWELL, P. G. DAVEY, and J. J. LAMBERT
- Antagonism of GABAA receptors by 4-quinolones
J. Antimicrob. Chemother. 1993. 31:457-462.[PDF]
- G. C. COOK
- Leishmaniasis: some recent developments in chemotherapy
J. Antimicrob. Chemother. 1993. 31:327-330.[PDF]
- H. STALEY, H. B. McDADE, and D. PAES
- Is an objective assessment of antibiotic therapy in exacerbations of chronic bronchitis possible?
J. Antimicrob. Chemother. 1993. 31:193-197.[PDF]
- STEVEN S. WITKIN and WILLIAM J. LEDGER
- New directions in the diagnosis and treatment of pelvic Inflammatory disease
J. Antimicrob. Chemother. 1993. 31:197-199.[PDF]
- PIETRO E. VARALDO
- The ‘borderline methicillin-susceptible’Staphylococcus aureus
J. Antimicrob. Chemother. 1993. 31:1-4.[PDF]
- SHARON E. PARKER and PETER G. DAVEY
- Practicalities of once-daily aminoglycoside dosing
J. Antimicrob. Chemother. 1993. 31:4-8.[PDF]
- IAN CHOPRA
- Effiux-based antibiotic resistance mechanisms: the evidence for increasing prevalence
J. Antimicrob. Chemother. 1992. 30:737-738.[PDF]
- P. RICHARD and L. GUTMANN
- Sparfloxacin and other new fluoroquinolones
J. Antimicrob. Chemother. 1992. 30:739-742.[PDF]
- M. J. G. Farthing
- Giardia comes of age: progress in epidemiology, immunology and chemotherapy
J. Antimicrob. Chemother. 1992. 30:563-666.[PDF]
- FRANCISCO SORIANO
- Optimal dosage of ß-lactam antibiotics: time above the MIC and inoculum effect
J. Antimicrob. Chemother. 1992. 30:567-569.[Abstract] [PDF]
- ANTHONY MAXWELL
- The molecular basis of quinolone action
J. Antimicrob. Chemother. 1992. 30:409-414.[PDF]
- U.B. SCHAAD and J. WEDGWOOD
- Lack of quinolone-induced arthropathy in children
J. Antimicrob. Chemother. 1992. 30:414-416.[PDF]
- ROGER G. FINCH
- BASC: 21 years
J. Antimicrob. Chemother. 1992. 30:416-416.[PDF]
- MICHAEL L. BENNISH and MOHAMMED A. SALAM
- Rethinking options for the treatment of shigellosis
J. Antimicrob. Chemother. 1992. 30:243-247.[PDF]
- WIDAD AL-NAKIB and DAVID A. J. TYRRELL
- Drugs against rhinoviruses
J. Antimicrob. Chemother. 1992. 30:115-117.[PDF]
- K.J. TOWNER
- Detection of antibiotic resistance genes with DNA probes
J. Antimicrob. Chemother. 1992. 30:1-2.[PDF]
- DAVID M. LIVERMORE
- Carbapenemases
J. Antimicrob. Chemother. 1992. 29:609-613.[PDF]
- GEORGE E. GRIFFIN
- New insights into the pathophysiology of the Jarisch-Herxheimer reaction
J. Antimicrob. Chemother. 1992. 29:613-616.[PDF]
- R. LANC and E. RUBINSTEIN
- Quinolones for tbe treatment of brucellosis
J. Antimicrob. Chemother. 1992. 29:357-360.[PDF]
- JEAN-DANIEL BAUMOARTNER
- Anti-endotoxin therapy and the management of sepsis
J. Antimicrob. Chemother. 1992. 29:360-363.[PDF]
- ROBERT E W. HANCOCK and FRANCIS BELLIDO
- Antibiotic uptake: unusual results for unusual molecules
J. Antimicrob. Chemother. 1992. 29:235-239.[PDF]
- ALASDAIR P. MACGOWAN
- When is pencillin monotherapy tbe antibiotic treatment of choice?
J. Antimicrob. Chemother. 1992. 29:239-243.[PDF]
- R. WISE
- Oral Cephalosporins
J. Antimicrob. Chemother. 1992. 29:91-92.[PDF]
- A. W. McKINLAY
- Antibiotics in the treatment of peptic ulcer disease
J. Antimicrob. Chemother. 1992. 29:92-96.[PDF]
- A. J. DAVIES and A. JOLLEY
- Antibacterial therapy of community-acquired chest infections
J. Antimicrob. Chemother. 1992. 29:1-4.[PDF]
- T. M. S. REID
- The treatment of non-typhi salmonellosis
J. Antimicrob. Chemother. 1992. 29:4-8.[PDF]
- HERBERT A. KIRST
- New macrolides: expanded horizons for an old class of antibiotics
J. Antimicrob. Chemother. 1991. 28:787-790.[PDF]
- CHRISTINE C. SANDERS
- ARTs versns ASTs: where are we going?
J. Antimicrob. Chemother. 1991. 28:621-623.[PDF]
- RICHARD D. MEYER
- Rote of the quinolones in the treatment of legionellosis
J. Antimicrob. Chemother. 1991. 28:623-625.[PDF]
- N. WOODFORD, A. P. JOHNSON, and R. C. GEORGE
- Detection of glycopeptide resistance in clinical isolates of Gram-positive bacteria
J. Antimicrob. Chemother. 1991. 28:483-486.[PDF]
- J. F. WESTPHAL, J. F. BLICKLE, and J. M. BROGARD
- Management of biliary tract infections: potential role of the qninoiones
J. Antimicrob. Chemother. 1991. 28:486-490.[PDF]
- M. J. TARLOW
- Adjunct therapy in bacterial meningitis
J. Antimicrob. Chemother. 1991. 28:329-332.[PDF]
- ROGER FINCH
- Hamao Umezawa Award
J. Antimicrob. Chemother. 1991. 28:332-332.[PDF]
- G. PHILLIPS and CLAYTON GOLLEDGE
- Fungal infection in neonates
J. Antimicrob. Chemother. 1991. 28:159-161.[PDF]
- FERNANDO BAQUERO
- From accuracy towards truth: the BSAC Working Party's guide to sensitivity testing
J. Antimicrob. Chemother. 1991. 27:701-702.[PDF]
- J.M.T. HAMILTON-MILLER
- From foreign pharmacopoeias: ‘new’ antibiotics from old?
J. Antimicrob. Chemother. 1991. 27:702-705.[PDF]
- M. R. W. BROWN, J. W. COSTERTON, and P. GILBERT
- Extrapolating to bacterial life outside the test tube
J. Antimicrob. Chemother. 1991. 27:565-567.[PDF]
- LAURA J. V. PIDDOCK
- Mechanism of quinolone uptake into bacterial cells
J. Antimicrob. Chemother. 1991. 27:399-403.[PDF]
- D. J. PAYNE and S. G. B. AMYES
- Transferable resistance to extended-spectrum ß-lactams: a major threat or a minor inconvenience?
J. Antimicrob. Chemother. 1991. 27:255-261.[PDF]
- ROBERT MILLER and SHARON STEEL
- Nebulized pentamidine as prophylaxis for Pneumocystis carinii pneumonia
J. Antimicrob. Chemother. 1991. 27:153-157.[PDF]
- GEORGE K. DAIKOS
- Continuous versus discontinuous antibiotic therapy: the role of the post-antibiotic effect and other factors
J. Antimicrob. Chemother. 1991. 27:157-160.[PDF]
- ROSAMOND A. COX
- Amantadine prophylaxis for health care workers: unanswered questions
J. Antimicrob. Chemother. 1991. 27:1-3.[PDF]
- M POWELL
- Chemotherapy for infections caused by Haemophilus influenzae: current problems and future prospects
J. Antimicrob. Chemother. 1991. 27:3-7.[PDF]
- IAN A. CRITCHLEY
- Catecholic ß-lactams: facilitated transport
J. Antimicrob. Chemother. 1990. 26:733-735.[Abstract] [PDF]
- R. C. SPENCER
- Temocillin
J. Antimicrob. Chemother. 1990. 26:735-737.[PDF]
- IAN CHOPRA
- Penetration of antibiotics to tbeir target sites
J. Antimicrob. Chemother. 1990. 26:607-609.[PDF]
- JULIE RIGHTER
- Agar dilution: standards and science, the cart before the bone
J. Antimicrob. Chemother. 1990. 26:609-611.[PDF]
- E. ANNE EADY, JEREMY I. ROSS, and JONATHAN H. COVE
- Multiple mechanisms of erythromycin resistance
J. Antimicrob. Chemother. 1990. 26:461-465.[PDF]
- ANNEMARIE POLAK
- Transport of the antimycotic 5-fluorocytosine and related substances in fungi
J. Antimicrob. Chemother. 1990. 26:465-468.[PDF]
- FRANCO MAGGIOLO, SEVERINO CAPRIOLI, and FREDY SUTER
- Risk/benefit analysis of quinolone use in children: the effect on diarthrodial Joints
J. Antimicrob. Chemother. 1990. 26:469-471.[PDF]
- J. L. MARTINEZ and F. BAQUERO
- Epidemiology of antibiotic-inactivating enzymes and DNA probes: the problem of quantity
J. Antimicrob. Chemother. 1990. 26:301-303.[PDF]
- W. ELIES
- Local chemotherapy of selected bacterial infections of the ear
J. Antimicrob. Chemother. 1990. 26:303-305.[PDF]
- T. G. WINSTANLEY
- Penicillin-induced post antibiotic effects on streptococci in vitro and in vivo
J. Antimicrob. Chemother. 1990. 26:165-168.[PDF]
- P. VAN DER AUWERA
- In-vitro tests of the functions of phagocytic cells and their interaction with antimicrobial agents: a critical view
J. Antimicrob. Chemother. 1990. 26:168-173.[PDF]
- BRIAN D. HOYLE, JANA JASS, and J. WILLIAM COSTERTON
- The biofilm glycocalyx as a resistance factor
J. Antimicrob. Chemother. 1990. 26:1-5.[PDF]
- R. WISE
- Macrolide progress
J. Antimicrob. Chemother. 1990. 26:5-6.[PDF]
- RONICA M. KLUGE
- Listeriosis-problems and therapeutic options
J. Antimicrob. Chemother. 1990. 25:887-890.[PDF]
- PER-ANDERS MARDH
- Treatment of pelvic inflammatory disease and related matters
J. Antimicrob. Chemother. 1990. 25:729-731.[PDF]
- DAVID SPELLER
- Double publication
J. Antimicrob. Chemother. 1990. 25:731-732.[PDF]
- B. D. Cookson
- Mupirocin resistance in staphylococci
J. Antimicrob. Chemother. 1990. 25:497-499.[PDF]
- I. M. GOULD
- Telcoplanin for prophylaxis of endocarditis after dental bacteraemia
J. Antimicrob. Chemother. 1990. 25:501-503.[PDF]
- D. F. J. BROWN
- The comparative methods of antimicrobial susceptibility testing—time for a change?
J. Antimicrob. Chemother. 1990. 25:307-309.[PDF]
- FIONA E. DONALD
- Treatment of brain abscess
J. Antimicrob. Chemother. 1990. 25:310-312.[PDF]
- B. CRYAN and D. J. M. WRIGHT
- Antimicrobial agents in Lyme disease
J. Antimicrob. Chemother. 1990. 25:187-190.[PDF]
- B. I. Davies and F. P. V. Maesen
- Treatment of Bramhamella catarrhalis infections
J. Antimicrob. Chemother. 1990. 25:1-4.[PDF]
- A. D. PITHIE and C. J. ELLIS
- Falciparum malaria: the current status of antimalarials in therapy and prophylaxis
J. Antimicrob. Chemother. 1990. 25:5-7.[PDF]
- KAREN BUSH
- Excitement in the ß-lactamase arena
J. Antimicrob. Chemother. 1989. 24:831-836.[PDF]
- JOHN G. BARTLETT
- Treatment of anaerobic pulmonary infections
J. Antimicrob. Chemother. 1989. 24:836-840.[PDF]
- Barrie J. Gatus, Sydney M. Bell, and Alex S. Jimenez
- A comparison of aztreonam and imipenem induction of Class I ß-lactamase in Enterobacter cloacae ATCC 13047
J. Antimicrob. Chemother. 1989. 24:841-849.[Abstract] [PDF]
- Jeremy I. Ross, Angela M. Farrell, E. Anne Eady, Jonathan H. Cove, and William J. Cunliffe
- Characterisation and molecular cloning of the novel macrolide-streptogramin B resistance determinant from Staphylococcus epidermidis
J. Antimicrob. Chemother. 1989. 24:851-862.[Abstract] [PDF]
- DAVID GREENWOOD
- Antibiotic resistance in enterococci
J. Antimicrob. Chemother. 1989. 24:631-635.[PDF]
- P.M. HAWKEY
- Where are we now with ciprofloxacin?
J. Antimicrob. Chemother. 1989. 24:477-480.[PDF]
- R.N. THIN
- Treatment of venereal syphilis
J. Antimicrob. Chemother. 1989. 24:481-483.[PDF]
- D. W. WARNOCK
- Itraconazole and fluconazole: new drugs for deep fungal infection
J. Antimicrob. Chemother. 1989. 24:275-276.[PDF]
- P. J. SANDERSON
- Preventing infection in orthopaedic implants
J. Antimicrob. Chemother. 1989. 24:277-280.[PDF]
- STUART B. LEVY
- Evolution and spread of tetracycline resistance determinants
J. Antimicrob. Chemother. 1989. 24:1-3.[PDF]
- HUGH J. FIELD
- The impact of drug resistance upon virus chemotherapy
J. Antimicrob. Chemother. 1989. 24:4-7.[PDF]
- L. E. BRYAN
- Two forms of antimicrobial resistance: bacterial persistence and positive function resistance
J. Antimicrob. Chemother. 1989. 23:817-820.[PDF]
- D. E. ROBERTS and J. D. WILLIAMS
- Ciprofloxacin in renal faliure
J. Antimicrob. Chemother. 1989. 23:820-823.[PDF]
- B. BACHI-BERGER
- Genetics of methicillin resistance in Staphylococeus aureus
J. Antimicrob. Chemother. 1989. 23:671-672.[PDF]
- W. W. NICHOLS
- The enigma of streptomycin transport
J. Antimicrob. Chemother. 1989. 23:673-676.[PDF]
- D. W. T. CHING, I. M. GOULD, J. A. N. RENNIE, and P. H. GIBSON
- Prevention of late haematogenous infection in major prostetic joints
J. Antimicrob. Chemother. 1989. 23:676-678.[PDF]
- L. J. V. PIDDOCK and R. WISE
- Mechanisms of resistance to quinolones and clinical perspectives
J. Antimicrob. Chemother. 1989. 23:475-480.[PDF]
- J. J. EARNSHAW
- Prevention of infection after vascular reconstruction
J. Antimicrob. Chemother. 1989. 23:480-483.[PDF]
- R. WISE
- The development of macrolides and related compounds
J. Antimicrob. Chemother. 1989. 23:299-300.[PDF]
- J. COHEN
- The clinical evaluation of antibacterial drugs
J. Antimicrob. Chemother. 1989. 23:175-176.[PDF]
- G. E. GRIFFIN
- Parenteral nutrition in septic shock
J. Antimicrob. Chemother. 1989. 23:176-177.[PDF]
- G. N. ROLINSON
- ß-Lactamase induction and resistance to ß-lactam antibiotics
J. Antimicrob. Chemother. 1989. 23:1-3.[PDF]
- M. W. McKENDRICK
- The chemotherapeutic approach to zoster
J. Antimicrob. Chemother. 1989. 23:3-5.[PDF]
- MICHAEL R. W. BROWN, DAVID G. ALLISON, and PETER GILBERT
- Resistance of bacterial biofilms to antibiotics a growth-rate related effect?
J. Antimicrob. Chemother. 1988. 22:777-780.[PDF]
- VINCENT G. BAIN and GRAEME J. M. ALEXANDER
- Progress in the treatment of chronic hepatitis B virus infection
J. Antimicrob. Chemother. 1988. 22:780-783.[PDF]
- J. HERITAGE and P. M. HAWKEY
- Tetracycline-resistant Neisseria gonorrhoeae
J. Antimicrob. Chemother. 1988. 22:575-579.[PDF]
- P. F. WHEAT and R. C. SPENCER
- The evolution of in-vitro antimicrobial susceptibility techniques
J. Antimicrob. Chemother. 1988. 22:579-582.[PDF]
- I. M. GOULD
- Control of antibiotic use in the United Kingdom
J. Antimicrob. Chemother. 1988. 22:395-397.[PDF]
- A. H. WILLIAMS and R. N. GRUNEBERG
- Teicoplanin revisited
J. Antimicrob. Chemother. 1988. 22:397-401.[PDF]
- D. A. LEIGH
- Use of quinolones in general practice
J. Antimicrob. Chemother. 1988. 22:269-271.[PDF]
- A. STANLEY TYMS and DEBRA L. TAYLOR
- Activity of glucosidase inhibitors against HIV infections
J. Antimicrob. Chemother. 1988. 22:271-274.[PDF]
- STEPHEN R. ALCOCK and IAIN McA. LEDINGHAM
- Selective decontamination of the digestive tract and prevention of infection in intensive care units
J. Antimicrob. Chemother. 1988. 22:97-104.[PDF]
- A. M. EMMERSON
- Cefuroxime axetil
J. Antimicrob. Chemother. 1988. 22:101-104.[PDF]
- BERNARD D. DAVIS
- The lethal action of aminoglycoside
J. Antimicrob. Chemother. 1988. 22:1-3.[PDF]
- H. PRUUL and P. J. MCDONALD
- Damage to bacteria by antibiotics in vitro and its relevance to antimicrobial chemotherapy: a historical perspective
J. Antimicrob. Chemother. 1988. 21:695-696.[PDF]
- R. A WALL
- The chemoprophylaxis of meningococcal infection
J. Antimicrob. Chemother. 1988. 21:698-699.[PDF]
- DAVID J. MORRIS
- Antiviral chemotherapy for cytomegalovirus disease
J. Antimicrob. Chemother. 1988. 21:519-520.[PDF]
- A.P.R. WILSON
- Antibiotic prophylaxis in cardiac surgery
J. Antimicrob. Chemother. 1988. 21:522-524.[PDF]
- A. J. DAVIES and D. S. KUMARATNE
- The continuing problem of pneumococcal infection
J. Antimicrob. Chemother. 1988. 21:387-391.[PDF]
- JOHN R. GIBSON
- The treatment of viral warts with interferons
J. Antimicrob. Chemother. 1988. 21:391-393.[PDF]
- LINDA MIZEN and GARY WOODNUTT
- A critique of pharmacokinetics
J. Antimicrob. Chemother. 1988. 21:273-278.[PDF]
- R. P. BAX
- Clinical trials and the pharmaceutical industry
J. Antimicrob. Chemother. 1988. 21:278-280.[PDF]
- IRMA A. J. M. BAKKER-WOUDENBERG and ROBERT ROOSENDAAL
- Impact of dosage regimens on the efficacy of antibiotics in the immunocompromised host
J. Antimicrob. Chemother. 1988. 21:145-147.[PDF]
- THOMAS V. RILEY
- Antimicrobial resistance in Branhamella catarrhalis
J. Antimicrob. Chemother. 1988. 21:147-150.[PDF]
- P. G. Davey
- Pharmacokinetics in liver disease
J. Antimicrob. Chemother. 1988. 21:1-8.[PDF]
- D. S. REEVES
- The effect of renal failure on the pharmacokinetics of antibiotics
J. Antimicrob. Chemother. 1988. 21:5-8.[PDF]
- IAN PHILLIPS
- Bacterial mntagenicity and the 4-quinolones
J. Antimicrob. Chemother. 1987. 20:771-773.[PDF]
- M. L. JOLY-GUILLOU, E. BERGOGNE-BEREZIN, and N. MOREAU
- Enzymatic resistance to ß-lactams and aminoglycosides in Acinetobacter calcoaceticus
J. Antimicrob. Chemother. 1987. 20:773-776.[PDF]
- F. D. DASCHNER and U. FRANK
- Antimicrobial drugs in human cardiac valves and endocarditic lesions
J. Antimicrob. Chemother. 1987. 20:776-782.[PDF]
- J. de LOUVOIS
- Pharmacokinetics of antibiotics in the newborn
J. Antimicrob. Chemother. 1987. 20:623-626.[PDF]
- A. J. BINT
- Pharmacokinetics of antibiotics in Peritoneal dialysis
J. Antimicrob. Chemother. 1987. 20:626-628.[PDF]
- MARTIN J. WOOD
- Interactions of antibiotics with other drugs
J. Antimicrob. Chemother. 1987. 20:628-630.[PDF]
- JULIE RIGHTER
- Treatment of coagulase-negative staphylococcal infections: dilemmas for laboratory and clinician
J. Antimicrob. Chemother. 1987. 20:459-462.[PDF]
- HENDRIK K. F. VAN SAENE and CHRISTIAAN P. STOUTENBEEK
- Selective decontamination
J. Antimicrob. Chemother. 1987. 20:462-465.[PDF]
- J. A. RAEBURN, J. R. W. GOVAN, W. M. McCRAE, A. P. GREENING, P. S. COLLIER, MARGARET E. HODSON, and MARY C. GOODCHILD
- Ciprofloxacin therapy in cystic fibrosis
J. Antimicrob. Chemother. 1987. 20:295-296.[PDF]
- E. M. BROWN
- Systemic antimicrobial prophylaxis in hysterectomy
J. Antimicrob. Chemother. 1987. 20:143-146.[PDF]
- R. J. HAY
- The azole antifungal drugs
J. Antimicrob. Chemother. 1987. 20:1-3.[PDF]
- T. HANNEDOUCHE and J.P. FILLASTRE
- Penicillin-induced hypersensitivity vasculitides
J. Antimicrob. Chemother. 1987. 20:3-5.[PDF]
- CRAIG R. SMITH
- The adverse effects of fluoroquinolones
J. Antimicrob. Chemother. 1987. 19:709-711.[PDF]
- DAVID C. E. SPELLER
- The relationship between the Journal and the pharmaceutical industry
J. Antimicrob. Chemother. 1987. 19:711-712.[PDF]
- L. A. JEWES
- Antimicrobial therapy of non-typhi salmonella and shigella infection
J. Antimicrob. Chemother. 1987. 19:557-560.[PDF]
- CHARLES W. STRATTON and FRANCISCA TAUSK
- Synergistic resistance mechanisms in Pseudomonas aeruginosa
J. Antimicrob. Chemother. 1987. 19:413-416.[PDF]
- CLIODNA A. M. McNULTY
- The treatment of campylobacter infections in man
J. Antimicrob. Chemother. 1987. 19:281-284.[PDF]
- HANNAH M. WEXLER and SYDNEY M. FINEGOLD
- Antimicrobial resistance in Bacteroides
J. Antimicrob. Chemother. 1987. 19:143-146.[PDF]
- M. W. CASEWELL and R. L. R. HILL
- Mupirocin (‘pseudomonic acid’)—a promising new topical antimicrobial agent
J. Antimicrob. Chemother. 1987. 19:1-5.[PDF]
- R. E. W. HANCOCK
- Intrinsic antibiotic resistance of Pseudomonas aeruginosa
J. Antimicrob. Chemother. 1986. 18:653-656.[PDF]
- M. FARRINGTON
- The prevention of wound infection after coronary artery bypass surgery
J. Antimicrob. Chemother. 1986. 18:656-659.[PDF]
- HILARY-KAY YOUNG
- Recent advances in the evolution of drug resistance
J. Antimicrob. Chemother. 1986. 16:679-680.[PDF]
- B. CHATTOPADHYAY
- Problems with diagnosis and antibiotic treatment of frequency and dysuria syndrome
J. Antimicrob. Chemother. 1986. 16:680-683.[PDF]
- IAN CHOPRA
- Antibiotics and bacterial adhesion
J. Antimicrob. Chemother. 1986. 18:553-554.[PDF]
- J. FRANCIS and S. W. B. NEWSOM
- Treatment of streptococcal and staphylococcal endocarditis
J. Antimicrob. Chemother. 1986. 18:554-556.[PDF]
- R. W. LACEY
- The mechanism of methicillin resistance
J. Antimicrob. Chemother. 1986. 18:435-436.[PDF]
- J. COHEN
- Anti-endotoxin immunotherapy in septic shock
J. Antimicrob. Chemother. 1986. 18:436-439.[PDF]
- A.-S. MALMBORG
- The renaissance of erythromycin
J. Antimicrob. Chemother. 1986. 18:293-296.[PDF]
- B. I. DAVIES and F. P. V. MAESEN
- Quinoiones in chest infections
J. Antimicrob. Chemother. 1986. 18:296-299.[PDF]
- P. M. HAWKEY
- The molecular evolution of antibiotic resistance genes in Gram-negative bacteria
J. Antimicrob. Chemother. 1986. 18:147-149.[PDF]
- W. A. GILLESPIE
- Antibiotics in catheterized patients
J. Antimicrob. Chemother. 1986. 18:149-151.[PDF]
- H. Y. CHEN
- Resistance of enterococci to antibiotic combinations
J. Antimicrob. Chemother. 1986. 18:1-4.[PDF]
- R. G. MASTERTON
- Antimicrobial prophylaxis in low-risk biliary surgery
J. Antimicrob. Chemother. 1986. 18:4-6.[PDF]
- ROGER FINCH
- ß-Lactam antibiotics and mycobacteria
J. Antimicrob. Chemother. 1986. 18:6-8.[PDF]
- H. OTTEN
- Domagk and the development of the sulphonamides
J. Antimicrob. Chemother. 1986. 17:689-690.[PDF]
- W. C. NOBLE
- The sulphonamides: an early British perspective
J. Antimicrob. Chemother. 1986. 17:690-693.[PDF]
- PETER BALL
- Toxicity of sulphonamide-diaminopyrimidine combinations: implications for future use
J. Antimicrob. Chemother. 1986. 17:694-696.[PDF]
- IRMA A. J. M. BAKKER-WOUDENBERG and FRITS H. ROERDINK
- Antimicrobial chemotherapy directed by liposomes
J. Antimicrob. Chemother. 1986. 17:547-549.[PDF]
- BO OBERG
- Antiviral chemotherapy against HTLV-III/LAV infections
J. Antimicrob. Chemother. 1986. 17:549-552.[PDF]
- ERIK DE CLERCQ
- Current leads in antiviral chemotherapy
J. Antimicrob. Chemother. 1986. 17:399-402.[PDF]
- WILLIAM H. BEGGS
- Mechanisms of synergistic interactions between amphotericin B and flucytosine
J. Antimicrob. Chemother. 1986. 17:402-404.[PDF]
- R. C. SPENCER and P. F. WHEAT
- Novel mechanisms for determining antibiotic susceptibilities
J. Antimicrob. Chemother. 1986. 17:404-407.[PDF]
- JAMES J. LIPSKY
- Testicular atrophy in animals—an effect of methiotetrazole-containing antibiotics
J. Antimicrob. Chemother. 1986. 17:267-268.[PDF]
- PETER E. REYNOLDS
- From whole organisms to crystallography: the changing face of the target of ß-lactam antibiotics
J. Antimicrob. Chemother. 1986. 17:129-131.[PDF]
- A. STANLEY TYMS
- Polyamine inhibitors
J. Antimicrob. Chemother. 1986. 17:131-135.[PDF]
- DAVID J. LEAPER and ROSEMARY A. SIMPSON
- The effect of antiseptics and topical antimicrobials on wound healing
J. Antimicrob. Chemother. 1986. 17:135-137.[PDF]
- C. S. GOODWIN and J. A. ARMSTRONG
- Will antibacterial chemotherapy be efficacious for gastritis and peptic ulcer?
J. Antimicrob. Chemother. 1986. 17:1-3.[PDF]
- E. BERGOGNE-BEREZIN and M. L. JOLY-GUILLOU
- An underestimated nosocomial pathogen, Acinetobacter calcoaceticus
J. Antimicrob. Chemother. 1985. 16:535-537.[PDF]
- C. S. F. EASMON
- Gonococcal resistance to antibiotics
J. Antimicrob. Chemother. 1985. 16:409-412.[PDF]
- ROBERTA. FONTANA
- Penicillin-binging proteins and the intrinsic resistance to ßlactams in Gram-positive cocci
J. Antimicrob. Chemother. 1985. 16:412-416.[PDF]
- B. WIEDEMANN, J. F. MEYER, B. A. NIES, and J. KRATZ
- Transposable multiresistance
J. Antimicrob. Chemother. 1985. 16:416-417.[PDF]
- ALASTAIR R. O. MILLER
- Antibiotics for expeditions
J. Antimicrob. Chemother. 1985. 16:277-279.[PDF]
- L. J. V. PIDDOCK and R. WISE
- Newer mechanisms of resistance to ß-lactam antibiotics in Gram-negative bacteria
J. Antimicrob. Chemother. 1985. 16:279-284.[PDF]
- MARK A. McKINLAY
- WIN 51711, a new systematically active broad-spectrum antipicornavirus agent
J. Antimicrob. Chemother. 1985. 16:284-286.[PDF]
- F. D. DASCHNER
- Antibiotics and host defence with special reference to phagocytosis by human polymorphonuclear leukocytes
J. Antimicrob. Chemother. 1985. 16:135-141.[PDF]
- JAMES E. PENNINGTON
- Animal models of pneumonia for evaluation of antimicrobial therapy
J. Antimicrob. Chemother. 1985. 16:1-4.[PDF]
- LOWELL S. YOUNG
- Double ß-lactam therapy in the immunocompromised host
J. Antimicrob. Chemother. 1985. 16:4-6.[PDF]
- DAVID GREENWOOD
- Phenotypic resistance to antimicrobial agents
J. Antimicrob. Chemother. 1985. 15:653-654.[PDF]
- J M T HAMILTON-MILLER
- Rationalization of terminology and methodology in the study of antibiotic interaction
J. Antimicrob. Chemother. 1985. 15:655-657.[PDF]
- D. M. LIVERMORE
- Do ß-lactamases ‘trap’ cephalosporins?
J. Antimicrob. Chemother. 1985. 15:511-514.[PDF]
- D C E. SPELLER and D W. WARNOCK
- Sensitivity and resistance to antifungals
J. Antimicrob. Chemother. 1985. 15:514-517.[PDF]
- S. P. F. HUGHES and F. M. ANDERSON
- Penetration of antibiotics into bone
J. Antimicrob. Chemother. 1985. 15:517-519.[PDF]
- RICHARD SLACK
- Bacterial Kinetic studies in infection
J. Antimicrob. Chemother. 1985. 15:519-521.[PDF]
- A. H. LINTON
- Antibiotic resistance in bacteria associated with animals and their importance to man
J. Antimicrob. Chemother. 1985. 15:385-386.[PDF]
- R BAYSTON
- Hydrocephalus shunt infections and their treatment
J. Antimicrob. Chemother. 1985. 15:259-261.[PDF]
- PETER G. CANONICO and PETER B JAHRUNG
- Chemotherapy for ‘exotic’ UNA virnses
J. Antimicrob. Chemother. 1985. 15:129-131.[PDF]
- URS B. SCHAAD
- Chemoprophylaxis of bacterial meningitis
J. Antimicrob. Chemother. 1985. 15:131-133.[PDF]
- KONRAD ANDRASSY, HEINRICH BECHTOLD, and EBERHARD RITZ
- Hvpoprothrombinemia caused by cephalosporins
J. Antimicrob. Chemother. 1985. 15:133-136.[PDF]
- DALE N. GERDING and LANCE R. PETERSON
- Serum protein binding and extrayascular distribution of antimicrobials
J. Antimicrob. Chemother. 1985. 15:136-138.[PDF]
- C. P. CONLON and C J. ELLIS
- Praziquantel
J. Antimicrob. Chemother. 1985. 15:1-2.[PDF]
- ANTHONY HART and DERRICK BAXBY
- Management of cryptosporidiosis
J. Antimicrob. Chemother. 1985. 15:3-4.[PDF]
- MICHEL G. BERGERO
- Therapeutic potential of high renal levels of aminoglycosides in pyelonephritis
J. Antimicrob. Chemother. 1985. 15:4-8.[PDF]
- T. G. B. HOWE
- The plasmids of Haemophilus ducreyi
J. Antimicrob. Chemother. 1984. 14:561-570.[PDF]
- ANONA BLACKWELL
- Teicoplanin
J. Antimicrob. Chemother. 1984. 14:441-445.[PDF]
- M. NEUMAN
- Recent developments in the field of phosphonic acid antibiotics
J. Antimicrob. Chemother. 1984. 14:309-311.[PDF]
- S. J. EYKYN
- Infection and intravenous catheters
J. Antimicrob. Chemother. 1984. 14:203-205.[PDF]
- RAGNAR NORRBY
- Quality of antibiotic clinical trials
J. Antimicrob. Chemother. 1984. 14:205-208.[PDF]
- H. MATTIE
- Animal models in antibacterial drug research
J. Antimicrob. Chemother. 1984. 14:101-102.[PDF]
- DAVID N. WILLIAMS, JUDITH A. GIBSON, and ALLAN C. KIND
- Outpatient intravenous antibiotic therapy
J. Antimicrob. Chemother. 1984. 14:102-104.[PDF]
- M. J. HALL
- Opportunities for the development and use of anti-herpes virus drug combinations
J. Antimicrob. Chemother. 1984. 13:529-534.[PDF]
- CURTIS G. GEMMELL
- Potentiation of phagocytosis of pathogenic bacteria by exposure to low concentrations of antibiotics
J. Antimicrob. Chemother. 1984. 13:407-409.[PDF]
- J. COHEN
- Empirical antifungal therapy in neutropenic patients
J. Antimicrob. Chemother. 1984. 13:409-411.[PDF]
- PATRICIA FENTON
- Treatment of peritonitis complicating continuous ambulatory peritoneal dialysis
J. Antimicrob. Chemother. 1984. 13:411-413.[PDF]
- J. M. OLESKE
- Effects of antimicrobials on host defence mechanism
J. Antimicrob. Chemother. 1984. 13:413-415.[PDF]
- J. M. T. HAMILTON-MILLER
- Binding of antibiotics by non-albumin proteins
J. Antimicrob. Chemother. 1984. 13:303-305.[PDF]
- ADRIAN G. TANNER
- Is pre-operative intra-incisional intra-parietal injection of antibiotics the ideal mode of administration as prophylaxis in abdominal surgery?
J. Antimicrob. Chemother. 1984. 13:305-308.[PDF]
- J .M GRANGE
- Therapy of infections caused by ‘atypical’ myco bacteria
J. Antimicrob. Chemother. 1984. 13:308-310.[PDF]
- C. J. ELLIS and P. L. CHIODINI
- The treatment of felciparum malaria
J. Antimicrob. Chemother. 1984. 13:311-314.[PDF]
- J. PHILPOTT-HOWARD
- Antibiotic resistance and Haemophilus influenzae
J. Antimicrob. Chemother. 1984. 13:199-200.[PDF]
- W. W. NICHOLS
- Aspects of the biochemistry of antimicrobial action
J. Antimicrob. Chemother. 1984. 13:200-204.[PDF]
- PETER DAVEY
- Comparative clinical trials of antimicrobial drugs
J. Antimicrob. Chemother. 1984. 13:204-208.[PDF]
- HELEN GIAMARELLOU
- Antibody-coated bacteria in urine: when, where and why?
J. Antimicrob. Chemother. 1984. 13:95-99.[PDF]
- CHRISTINE C. SANDERS
- Inducible ß-lactamases and non-hydrolytic resistance mechanisms
J. Antimicrob. Chemother. 1984. 13:1-3.[PDF]
- JEAN-CLAUDE PECHERE and ROGER LEVESQUE
- ß-lactamases: clinical and genetic perspectives
J. Antimicrob. Chemother. 1983. 12:529-532.[PDF]
- V. J. RICHARDSON
- Liposomes in antimicrobial chemotherapy
J. Antimicrob. Chemother. 1983. 12:532-534.[PDF]
- MARTIN THOMAS
- Antibiotics in bile
J. Antimicrob. Chemother. 1983. 12:419-422.[PDF]
- J. D. ANDERSON
- Application of non-animal models to studies of the chemotherapy of bacterial urinary tract infections
J. Antimicrob. Chemother. 1983. 12:297-300.[PDF]
- F. J. NYE
- Partial treatment and partial diagnosis in pyogenic meningitis
J. Antimicrob. Chemother. 1983. 12:300-301.[PDF]
- IAN PHILLIPS
- Supplements
J. Antimicrob. Chemother. 1983. 12:199-200.[PDF]
- H. LODE
- Combination therapy with ß-lactam antibiotics
J. Antimicrob. Chemother. 1983. 12:200-203.[PDF]
- S. H. NORRIS
- The diagnosis and management of septic arthritis in children
J. Antimicrob. Chemother. 1983. 12:203-204.[PDF]
- JOHN DE LOUVOIS
- Antimicrobial chemotherapy in the treatment of brain abscess
J. Antimicrob. Chemother. 1983. 12:205-207.[PDF]
- AGNETA PHILIPSON
- The use of antibiotics in pregnancy
J. Antimicrob. Chemother. 1983. 12:101-102.[PDF]
- JEAN KLASTERSKY
- Management of infection in granulocytopenic patients
J. Antimicrob. Chemother. 1983. 12:102-104.[PDF]
- M.R.B. KEIGHLEY
- Clostridium difficile and inflammatory bowel disease
J. Antimicrob. Chemother. 1983. 11:493-494.[PDF]
- DAVID L. MORRIS
- Chemotherapy of hydatid disease
J. Antimicrob. Chemother. 1983. 11:494-496.[PDF]
- CRAIG R. SMITH and JAMES J. LIPSKY
- Hypoprothrombinemia and platelet dysfunction caused by cephalosporin and oxalactam antibiotics
J. Antimicrob. Chemother. 1983. 11:496-498.[PDF]
- JOHN D. TURNIDGE and WILLIAM A. CRAIG
- ß-Lactam pharmacology in liver disease
J. Antimicrob. Chemother. 1983. 11:499-501.[PDF]
- JOHN H. NEWMAN
- The prevention of infection in open fractures
J. Antimicrob. Chemother. 1983. 11:391-392.[PDF]
- DAVID MAXWELL
- The role of antibiotics given by inhalation in chronic chest disease
J. Antimicrob. Chemother. 1983. 11:203-206.[PDF]
- P. M. WATERWORTH
- Changes in sensitivity testing
J. Antimicrob. Chemother. 1983. 11:1-2.[PDF]
- R. W. LACEY
- Treatment of staphylococcal infections
J. Antimicrob. Chemother. 1983. 11:3-6.[PDF]
- A. G. BROWN
- ß-Lactam nomenclature
J. Antimicrob. Chemother. 1982. 10:365-368.[PDF]
- MARY P. E. SLACK and W. W. NICHOLS
- Antibiotic penetration through bacterial capsules and exopolysaccharides
J. Antimicrob. Chemother. 1982. 10:368-372.[PDF]
- S. W. B. NEWSOM
- Vancomycin
J. Antimicrob. Chemother. 1982. 10:257-259.[PDF]
- PRAMOD M. SHAH
- Paradoxical effect of antibiotics: I. The‘Eagle effect’
J. Antimicrob. Chemother. 1982. 10:259-260.[PDF]
- D. I. ANNEAR
- Paradoxical effect of antibiotics: II. Comment and bibliography
J. Antimicrob. Chemother. 1982. 10:260-262.[PDF]
- ISOBEL ROSENSTEIN
- Therapeutic applications of urease inhibitors
J. Antimicrob. Chemother. 1982. 10:159-161.[PDF]
- J. S. OXFORD
- New biochemical and clinical approaches to the control of epidemic influenza virus?
J. Antimicrob. Chemother. 1982. 10:161-163.[PDF]
- D. W. WARNOCK and D. C. E. SPELLER
- Antifungals today
J. Antimicrob. Chemother. 1982. 10:164-167.[PDF]
- D. M. LIVERMORE
- ß-lactamases of Pseudomonas aeruginosa
J. Antimicrob. Chemother. 1982. 10:168-171.[PDF]
- N.J. BEECHING and C.J. ELLIS
- Leprosy and its chemotherapy
J. Antimicrob. Chemother. 1982. 10:81-84.[PDF]
- H.R. INGHAM, PENELOPER SISSON, and J.B. SELKON
- Interactions between micro-organisms and metronidazole
J. Antimicrob. Chemother. 1982. 10:84-87.[PDF]
- D. M. GEDDES
- Pseudomonas in the chest
J. Antimicrob. Chemother. 1982. 10:1-2.[PDF]
- N. WRIGHT
- The clinical relevance of pharmacokinetics
J. Antimicrob. Chemother. 1982. 10:2-4.[PDF]
- M. J. BASKER
- The carbapenem family
J. Antimicrob. Chemother. 1982. 10:4-7.[PDF]
- A. J. DAVIES
- Testing, reporting and prescribing antibiotics for urinary infections
J. Antimicrob. Chemother. 1982. 10:7-9.[PDF]
- R. GOKAL
- Peritonitis in continuous ambulatory peritoneal dialysis
J. Antimicrob. Chemother. 1982. 9:417-420.[PDF]
- J. L. BIDWELL
- Applications and relevance of plasmid analysis in clinical microbiology laboratories
J. Antimicrob. Chemother. 1982. 9:420-422.[PDF]
- A. PINES
- The tetracyclines in purulent exacerbations of chronic bronchitis
J. Antimicrob. Chemother. 1982. 9:333-335.[PDF]
- B. CHATTOPADHYAY
- Antibiotics in suspected neonatal meningitis
J. Antimicrob. Chemother. 1982. 9:335-338.[PDF]
- LOWELL S. YOUNG
- The outlook for antifugal prophylaxis in the compromised host
J. Antimicrob. Chemother. 1982. 9:338-340.[PDF]
- D. A. J. TYRRELL and R. PHILLPOTTS
- Antirhinovirus drugs
J. Antimicrob. Chemother. 1982. 9:340-341.[PDF]
- S. LEVIN and G. M. TRENHOLME
- Narrow versus broad-spectrum therapy
J. Antimicrob. Chemother. 1982. 9:247-249.[PDF]
- TRACY D. WILKINS
- Chemotherapy of Experimental Anaerobic Infections
J. Antimicrob. Chemother. 1982. 9:249-251.[PDF]
- A. PINES
- Successful treatment of respiratory tract infections in patients with chronic respiratory disease—how to make objective conclusions
J. Antimicrob. Chemother. 1982. 9:165-168.[PDF]
- M. WENK
- Concepts for aminoglycoside serum level monitoring
J. Antimicrob. Chemother. 1982. 9:168-169.[PDF]
- J. M. T. HAMILTON-MILLER
- ß-Lactamase—a human enzyme, too
J. Antimicrob. Chemother. 1982. 9:87-88.[PDF]
- DAVID CHADWICK
- Antibiotics and benign intracranial hypertension
J. Antimicrob. Chemother. 1982. 9:88-90.[PDF]
- R. FRASER WILLIAMS
- Choice of chemotherapy for infection by Staphylococcus aureus
J. Antimicrob. Chemother. 1982. 9:1-3.[PDF]
- I. M. GOULD
- 12th International Congress of Chemo-therapy Florence—19–24 July 1981
J. Antimicrob. Chemother. 1982. 9:3-5.[PDF]
- D. C. SHANSON
- Short-course treatment of streptococcal endocarditis
J. Antimicrob. Chemother. 1981. 8:427-428.[PDF]
- S. C. GLOVER and A. M. GEDDES
- Treatment of pyogenic osteomylitis
J. Antimicrob. Chemother. 1981. 8:347-349.[PDF]
- S. DAROUGAR
- Chlamydial ocular infection
J. Antimicrob. Chemother. 1981. 8:350-354.[PDF]
- A. M. GEDDES
- Antibiotics and travellers' diarrhoea
J. Antimicrob. Chemother. 1981. 8:247-248.[PDF]
- MARY P. E. SLACK
- Antipseudomonal ß-lactams
J. Antimicrob. Chemother. 1981. 8:165-170.[PDF]
- NIGEL A. C. CURTIS
- Penicillin-binding proteins in theory and practice
J. Antimicrob. Chemother. 1981. 8:85-87.[PDF]
- N. J. RUSSELL
- Treatment of Pneumocystis carini pneumonia
J. Antimicrob. Chemother. 1981. 8:87-89.[PDF]
- L. O. WHITE
- HPLC in clinical microbiology laboratories
J. Antimicrob. Chemother. 1981. 8:1-3.[PDF]
- C. M. M. stern
- Bactericidal glycopeptide in human amniotic fluid
J. Antimicrob. Chemother. 1981. 8:3-4.[PDF]
- D. A. LEIGH
- Who knows the cost of antibiotics?
J. Antimicrob. Chemother. 1981. 7:589-590.[PDF]
- J.G. GOW
- The management of genitourinary tuberculosis
J. Antimicrob. Chemother. 1981. 7:590-591.[PDF]
- JENNIFER CLAY
- Non-specific vaginitis: its diagnosis and treatment
J. Antimicrob. Chemother. 1981. 7:501-503.[PDF]
- R. WISE
- After pro-drugs—mutual pro-drugs
J. Antimicrob. Chemother. 1981. 7:503-504.[PDF]
- E. S. HARPUR and P. G. DAVEY
- Toxic effects of aminoglycosides
J. Antimicrob. Chemother. 1981. 7:313-315.[PDF]
- R. MASKELL
- Should ‘fastidious’ organisms alter our approach to the treatment of uninary symptoms?
J. Antimicrob. Chemother. 1981. 7:315-317.[PDF]
- D. F. J. BROWN
- Animal models as predictors of therapeutic efficacy in bacterial infections in humans
J. Antimicrob. Chemother. 1981. 7:213-215.[PDF]
- F. J. NYE
- Do antibiotics really prolong salmonella excretion?
J. Antimicrob. Chemother. 1981. 7:215-216.[PDF]
- HERBERT M. GILLES
- The treatment of schistosomiasis
J. Antimicrob. Chemother. 1981. 7:113-114.[PDF]
- J. R. WALTON
- Therapeutic antibiotics in veterinary practice
J. Antimicrob. Chemother. 1981. 7:114-115.[PDF]
- B. ROWE and E.J. THRELFALL
- Multiple antimicrobial drug resistance in enteric pathogens
J. Antimicrob. Chemother. 1981. 7:1-3.[PDF]
- IAN PHILLIPS
- Change of Editor
J. Antimicrob. Chemother. 1981. 7:1-1.[PDF]
- ROGER FINCH
- Immunomodulating effects of antimicrobial agents
J. Antimicrob. Chemother. 1980. 6:691-694.[PDF]
- J. OXFORD
- The potential of phosphonoformate for the treatment of herpes simplex labialis
J. Antimicrob. Chemother. 1980. 6:694-695.[PDF]
- I. D. FARRELL and L. R. ROBERTSON
- The treatment of brucellosis
J. Antimicrob. Chemother. 1980. 6:695-697.[PDF]
- A. J. BINT
- Esters of penicillins—are they hepatotoxic?
J. Antimicrob. Chemother. 1980. 6:697-699.[PDF]
- R. W. LACEY
- Bacteriophages and spread of resistance in Staphylococcus aureus
J. Antimicrob. Chemother. 1980. 6:567-568.[PDF]
- J. R. GIBSON
- The treatment of acne
J. Antimicrob. Chemother. 1980. 6:568-570.[PDF]
- E. THOMAS
- Towards better antimicrobial treatment of sexually transmitted diseases
J. Antimicrob. Chemother. 1980. 6:570-573.[PDF]
- W. EDMUND FARRAR
- Building better ß-lactams
J. Antimicrob. Chemother. 1980. 6:573-575.[PDF]
- E. P. ABRAHAM
- Ernst Chain and Paul Garrod
J. Antimicrob. Chemother. 1980. 6:423-424.[PDF]
- HANNAH FARKAS-HIMSLEY
- Bacteriocins—are they broad-spectrum antibiotics?
J. Antimicrob. Chemother. 1980. 6:424-427.[PDF]
- CLAUS OLA SOLBERG
- Systemic antibiotic prophylaxis in surgery
J. Antimicrob. Chemother. 1980. 6:427-430.[PDF]
- K. P. SHANNON
- New cephalosporins and related compounds
J. Antimicrob. Chemother. 1980. 6:430-433.[PDF]
- A. M. EMMERSON
- The need for a pneumococcal vaccine
J. Antimicrob. Chemother. 1980. 6:301-303.[PDF]
- S. G. B. AMYES
- Boston: mechanisms of antimicrobial drug resistance
J. Antimicrob. Chemother. 1980. 6:303-305.[PDF]
- C. J. ELLIS
- How should we use metronidazole?
J. Antimicrob. Chemother. 1980. 6:305-307.[PDF]
- J. L. MADDOCKS
- Indirect pathogenicity
J. Antimicrob. Chemother. 1980. 6:307-309.[PDF]
- P. J. NICHOLLS
- Neurotoxicity of penicillin
J. Antimicrob. Chemother. 1980. 6:161-165.[PDF]
- R. P. MOUTON
- Choice of an aminoglycoside
J. Antimicrob. Chemother. 1980. 6:166-168.[PDF]
- D. C. E. SPELLER
- Hospital infection by multi-resistant Gramnegative bacilli
J. Antimicrob. Chemother. 1980. 6:168-170.[PDF]
- J. D. ANDERSON
- Single dose treatment of acute urinary infections in women
J. Antimicrob. Chemother. 1980. 6:170-172.[PDF]
- A. KUCERS
- Current position of chloramphenicol chemotherapy
J. Antimicrob. Chemother. 1980. 6:1-4.[PDF]
- W. EDMUND FARRAR
- Gentamicin transposons
J. Antimicrob. Chemother. 1980. 6:4-5.[PDF]
- A. M. EMMERSON
- More about antibiotic policies
J. Antimicrob. Chemother. 1980. 6:6-7.[PDF]
- D. BELL
- Chemoprophylaxis in malaria
J. Antimicrob. Chemother. 1980. 6:7-9.[PDF]
- ELIZABETH J. SHAW
- Immunoassays for antibiotics
J. Antimicrob. Chemother. 1979. 5:625-628.[PDF]
- M. J. SERLIN
- Antimicrobial drug interactions with oral anticoagulants
J. Antimicrob. Chemother. 1979. 5:628-630.[PDF]
- RAGNAR NORRBY
- Pharmacokinetic aspects of the treatment of infections in the central nervous system
J. Antimicrob. Chemother. 1979. 5:630-633.[PDF]
- P. G. WELLING
- The esters of erythromycin
J. Antimicrob. Chemother. 1979. 5:633-634.[PDF]
- A. M. CLARKE
- Prophylactic antibiotics for total hip arthroplasty—the significance of Staphylococcus epidermidis
J. Antimicrob. Chemother. 1979. 5:493-495.[PDF]
- M. W. MCKENDRICK
- Erythromycin revisited
J. Antimicrob. Chemother. 1979. 5:495-497.[PDF]
- DONALD A. LEIGH
- Treatment of familial staphytococcal infection
J. Antimicrob. Chemother. 1979. 5:497-499.[PDF]
- DAVID I. EDWARDS
- Mechanism of antimicrobial action of metronidazole
J. Antimicrob. Chemother. 1979. 5:499-502.[PDF]
- H. LAMBERT
- Antimicrobial drugs in the treatment and prevention of pertussis
J. Antimicrob. Chemother. 1979. 5:329-331.[PDF]
- HAROLD C. NEU
- Prophylaxis—has it at last come of age?
J. Antimicrob. Chemother. 1979. 5:331-333.[PDF]
- J. S. OXFORD
- Inhibition of herpes virus by a new compound—acyclic guanosine
J. Antimicrob. Chemother. 1979. 5:333-334.[PDF]
- C. C. EVANS
- Management of pulmonary disorders caused by the inhalation of aspergillus spores
J. Antimicrob. Chemother. 1979. 5:335-336.[PDF]
- CHATRCHAI WATANAKUNAKORN
- Are wall-defective microbial variants important in clinical infectious diseases?
J. Antimicrob. Chemother. 1979. 5:239-241.[PDF]
- R. J. FALLON
- Yersinia enterocolitica epidemiology and antibiotic susceptibility
J. Antimicrob. Chemother. 1979. 5:241-244.[PDF]
- F. J. NYE
- Treating toxoplasmosis
J. Antimicrob. Chemother. 1979. 5:244-246.[PDF]
- H. H. JOHNSTON
- Automation for sensitivity testing
J. Antimicrob. Chemother. 1979. 5:246-247.[PDF]
- RICHARD WISE
- Antimicrobial potentiating agents
J. Antimicrob. Chemother. 1979. 5:121-122.[PDF]
- H. LODE
- Penetration of antibiotics into the pleural fluid
J. Antimicrob. Chemother. 1979. 5:122-124.[PDF]
- M. L'E. ORME and D. J. BACK
- Therapy with oral contraceptive steroids and antibiotics
J. Antimicrob. Chemother. 1979. 5:124-126.[PDF]
- JULIAN VERBOV
- Local idoxuridine treatment of herpes simplex and zoster
J. Antimicrob. Chemother. 1979. 5:126-128.[PDF]
- GEORGE GEE JACKSON
- Antibiotic policies, practices and pressures
J. Antimicrob. Chemother. 1979. 5:1-4.[PDF]
- W. C. BUSS
- Induction of hepatic drag metabolizing enzymes and pregnancy while taking oral contraceptives
J. Antimicrob. Chemother. 1979. 5:4-5.[PDF]
- M. R. JACOBS and H. J. KOORNHOF
- Multiple-antibiotic resistance—now the pneumococcus
J. Antimicrob. Chemother. 1978. 4:481-483.[PDF]
- A.-S. MALMBORG
- Antimicrobial drugs in human seminal plasma
J. Antimicrob. Chemother. 1978. 4:483-485.[PDF]
- J. A. WASHINGTON
- Treatment of bacteraemia due to anaerobic bacteria
J. Antimicrob. Chemother. 1978. 4:485-486.[PDF]
- D. A. MCGOWAN
- Failure of prophylaxis of Infective endocarditis following dental treatment
J. Antimicrob. Chemother. 1978. 4:486-488.[PDF]
- S. W. B. NEWSOM
- Antibiotic prophylaxis for open-heart surgery
J. Antimicrob. Chemother. 1978. 4:389-391.[PDF]
- R. W. LACEY
- The suppression of the appearance of bacterial mutants by combined antibacterial therapy
J. Antimicrob. Chemother. 1978. 4:391-392.[PDF]
- JOHN C. BARTLETT
- Antimicroblal therapy in experimental intra-abdominal sepsls
J. Antimicrob. Chemother. 1978. 4:392-394.[PDF]
- C. STUART-HARRIS
- Amantadine—what next?
J. Antimicrob. Chemother. 1978. 4:295-297.[PDF]
- R. BAGG
- Antibiotic treatment of staphylococcal pneumonia in adults
J. Antimicrob. Chemother. 1978. 4:297-299.[PDF]
- F. P. TALLY
- Factors affecting antimicrobial agents in an anaerobic abscess
J. Antimicrob. Chemother. 1978. 4:299-302.[PDF]
- M. GURWITH
- Prevention of infection in leukaemia
J. Antimicrob. Chemother. 1978. 4:302-304.[PDF]
- J. M. T. HAMILTON-MILLER
- Too many ampicillins?
J. Antimicrob. Chemother. 1978. 4:193-195.[PDF]
- D. A. LEIGH
- Clostridium sordelli and antibiotic-associated pseudomembranous colitis
J. Antimicrob. Chemother. 1978. 4:195-198.[PDF]
- ROGER G. FINCH
- Treatment of Lancefield group B streptococcal infections
J. Antimicrob. Chemother. 1978. 4:198-199.[PDF]
- JANE M. SYMONDS
- Aminoglycoside ototoxicity
J. Antimicrob. Chemother. 1978. 4:199-201.[PDF]
- F. P. MARSH
- Do cephalosporins potentiate or antagonize aminoglycoside nepharotoxcity?
J. Antimicrob. Chemother. 1978. 4:103-106.[PDF]
- R. J. FALLON
- Antibiotic therapy in Legionnaire's disease
J. Antimicrob. Chemother. 1978. 4:106-107.[PDF]
- B. WATT
- Streptococcal endocarditis: a penicillin alone or a penicillin with an aminoglycoside?
J. Antimicrob. Chemother. 1978. 4:107-109.[PDF]
- J. D. WILLIAMS
- Which cephalosporin?
J. Antimicrob. Chemother. 1978. 4:109-111.[PDF]
- BSAC Symposium on Antifungal Therapy
J. Antimicrob. Chemother. 1978. 4:111-112.[PDF]
- R. J. FALLON
- The treatment of tuberculous meningitis
J. Antimicrob. Chemother. 1978. 4:1-2.[PDF]
- D. C. SHANSON
- The prophylaxis of infective endocarditis
J. Antimicrob. Chemother. 1978. 4:2-4.[PDF]
- PAMELA M. WATERWORTH
- Uniformity in sensitivity test media
J. Antimicrob. Chemother. 1978. 4:4-6.[PDF]
- J. D. WILLIAMS
- Spread of R-factors outside the Enterobacteriaceae
J. Antimicrob. Chemother. 1978. 4:6-8.[PDF]
- JOHN GRAY
- Synergy and mecillinam
J. Antimicrob. Chemother. 1977. 3:531-533.[PDF]
- D. S. REEVES
- Prescription of aminoglycosides by nomogram
J. Antimicrob. Chemother. 1977. 3:533-535.[PDF]
- A. J. HOWARD
- Ampicillin resistance in Haemophilus influenzae
J. Antimicrob. Chemother. 1977. 3:535-538.[PDF]
- J. S. OXFORD
- Control of herpes virus infections by drugs or vaccines?
J. Antimicrob. Chemother. 1977. 3:538-539.[PDF]
- E. M. C. DUNLOP
- Treatment of patients suffering from chlamydial infections
J. Antimicrob. Chemother. 1977. 3:377-379.[PDF]
- RICHARD LACEY
- A new type of penicillin resistance of Staphylococcus aureus?
J. Antimicrob. Chemother. 1977. 3:380-381.[PDF]
- H. P. LAMBERT
- Problems with neonatal meningitis
J. Antimicrob. Chemother. 1977. 3:381-382.[PDF]
- A. M. GEDDES
- The antibiotic treatment of typhoid fever
J. Antimicrob. Chemother. 1977. 3:382-383.[PDF]
- RICHARD WISE
- Substituted ampicillins
J. Antimicrob. Chemother. 1977. 3:289-290.[PDF]
- J. H. ANGEL
- Short-course chemotherapy in pulmonary tuberculosis
J. Antimicrob. Chemother. 1977. 3:290-293.[PDF]
- N. SLADE
- Chemotherapy of urinary tract infections in children
J. Antimicrob. Chemother. 1977. 3:294-296.[PDF]
- J. M. T. HAMILTON-MILLER
- Inhibition of ß-lactamase: a continuing story
J. Antimicrob. Chemother. 1977. 3:195-196.[PDF]
- A. E. WILKINSON
- The sensitivity of gonococci to penicillin
J. Antimicrob. Chemother. 1977. 3:197-198.[PDF]
- M. R. W. BROWN
- Nutrient depletion and antibiotic susceptibility
J. Antimicrob. Chemother. 1977. 3:198-200.[PDF]
- S. W. B. NEWSOM
- Rapid sensitivity tests
J. Antimicrob. Chemother. 1977. 3:201-202.[PDF]
- N. A. SIMMONS
- Synergy and rifampicin
J. Antimicrob. Chemother. 1977. 3:109-111.[PDF]
- G. N. ROLINSON
- Subinhibitory concenfrations of antibiotics
J. Antimicrob. Chemother. 1977. 3:111-113.[PDF]
- D. GERAINT JAMES
- Crohn's picorna enteritis
J. Antimicrob. Chemother. 1977. 3:113-114.[PDF]
- J. D. WILLIAMS
- 10th International Congress of Chemotherapy
J. Antimicrob. Chemother. 1977. 3:114-114.[PDF]
- PAMELA M. WATERWORTH
- Which gentamicin assay method is the most practicable?
J. Antimicrob. Chemother. 1977. 3:1-2.[PDF]
- NORMAN SLADE
- Urinary tract infection in neurogenic bladder
J. Antimicrob. Chemother. 1977. 3:3-5.[PDF]
- D. GERAINT JAMES
- Travellers' diarrhoea
J. Antimicrob. Chemother. 1977. 3:5-6.[PDF]
- DAVID GREENWOOD
- Enterobacterial ß-lactamases
J. Antimicrob. Chemother. 1977. 3:7-8.[PDF]
- A. P. BALL
- Serratia marcescens infections—selection of an antibiotic
J. Antimicrob. Chemother. 1976. 2:317-319.[PDF]
- D. G. JAMES
- Epidemiology of anthrax
J. Antimicrob. Chemother. 1976. 2:319-320.[PDF]
- D. HUGHES
- Chemoprophylaxis in chronic bronchitis
J. Antimicrob. Chemother. 1976. 2:320-322.[PDF]
- J. F. MUNRO
- Diabetes and infection
J. Antimicrob. Chemother. 1976. 2:322-324.[PDF]
- J. S. OXFORD
- Drug resistance and antiviral agents
J. Antimicrob. Chemother. 1976. 2:223-224.[PDF]
- H. R. INGHAM and J. B. SELKON
- Cerebral abscess
J. Antimicrob. Chemother. 1976. 2:224-225.[PDF]
- A. J. BINT
- Gentamicin-resistant Staphylococcus aureus
J. Antimicrob. Chemother. 1976. 2:225-226.[PDF]
- J. D. ANDERSON
- The relevance of urine and serum antibacterial activity to the treatment of urinary tract infections
J. Antimicrob. Chemother. 1976. 2:226-228.[PDF]
- R. L. PARSONS
- Antibiotics in bone
J. Antimicrob. Chemother. 1976. 2:228-231.[PDF]
- J. A. RAEBURN
- Antibiotic management of cystic fibrosis
J. Antimicrob. Chemother. 1976. 2:107-109.[PDF]
- G. D. CHISHOLM
- Preventing casualty wound infection
J. Antimicrob. Chemother. 1976. 2:109-110.[PDF]
- S. BELL
- The relevance of bacteriology tests to the clinical use of antibiotics in domiciliary practice
J. Antimicrob. Chemother. 1976. 2:110-112.[PDF]
- CHARLES STUART-HARRIS
- The present status of idoxuridine
J. Antimicrob. Chemother. 1976. 2:112-114.[PDF]
- FRANCIS O'GRADY
- Animal models in the assessment of antimicrobial agents
J. Antimicrob. Chemother. 1976. 2:1-3.[PDF]
- H. P. LAMBERT
- Birthday greetings to L.P.G.
J. Antimicrob. Chemother. 1976. 2:1-1.[PDF]
- R. J. FALLON
- Haemophilus influenzae meningitis
J. Antimicrob. Chemother. 1976. 2:3-5.[PDF]
- J. M. T. HAMILTON-MILLER and W. BRUMFITT
- The versatility of nitro compounds
J. Antimicrob. Chemother. 1976. 2:5-8.[PDF]
- A. M. GEDDES
- Chloroquine in malaria chemotherapy
J. Antimicrob. Chemother. 1975. 1:349-350.[PDF]
- D. S. REEVES
- Extra-vascular injections of antibiotics
J. Antimicrob. Chemother. 1975. 1:350-353.[PDF]
- JOHN MORRISON-SMITH
- Rifampicin in clinical use
J. Antimicrob. Chemother. 1975. 1:353-354.[PDF]
- D. C. E. SPELLER
- Yeasts in the urine
J. Antimicrob. Chemother. 1975. 1:253-254.[PDF]
- A. T. WILLIS
- A view of bacteroides
J. Antimicrob. Chemother. 1975. 1:254-255.[PDF]
- GRAHAM A. J. AYLIFFE
- Antibiotic policies
J. Antimicrob. Chemother. 1975. 1:255-257.[PDF]
- N. A. SIMMONS
- Antibiotic synergy
J. Antimicrob. Chemother. 1975. 1:257-261.[PDF]
- STUART-HARRIS CHARLES
- Prospects for antiviral chemotherapy
J. Antimicrob. Chemother. 1975. 1:133-134.[PDF]
- MARWAN UWAYDAH
- Choice of antimicrobial agents in enteric fever
J. Antimicrob. Chemother. 1975. 1:135-137.[PDF]
- S. W. B. NEWSOM
- Anaerobes unlimited
J. Antimicrob. Chemother. 1975. 1:137-137.[PDF]
- B. T. MARSH
- The trials of clinical trials
J. Antimicrob. Chemother. 1975. 1:138-138.[PDF]
- J. D. WILLIAMS
- International Congress
J. Antimicrob. Chemother. 1975. 1:139-139.[PDF]
- Brian Wells Pence
- The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS
[Abstract] [Full Text] [PDF]
- Roger Finch and Mike Sharland
- 18 November and beyond: observations on the EU Antibiotic Awareness Day
[Abstract] [Full Text] [PDF]
- Linos Vandekerckhove, Chris Verhofstede, and Dirk Vogelaers
- Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients
[Abstract] [Full Text] [PDF]
- Kay Seden, David Back, and Saye Khoo
- Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable
[Abstract] [Full Text] [PDF]
- Stephan Ludwig
- Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy
[Abstract] [Full Text] [PDF]
- Martin Sundqvist and Gunnar Kahlmeter
- ‘Pre-emptive culturing’ will improve the chance of ‘getting it right’ when empirical therapy of urinary tract infections fails
[Abstract] [Full Text] [PDF]
- Vincent Wai-Sun Wong and Joseph Jao-Yiu Sung
- Antiviral therapy for chronic hepatitis B: are we doing any good to patients?
[Abstract] [Full Text] [PDF]
- Alan Percival
- Appreciation
[Full Text] [PDF]
- Stephen Taylor, Ashini Jayasuriya, and Erasmus Smit
- Using HIV resistance tests in clinical practice
[Abstract] [Full Text] [PDF]
- Jake Dunning and Mark Nelson
- Novel strategies to treat antiretroviral-naive HIV-infected patients
[Abstract] [Full Text] [PDF]
- Giovanni Guaraldi and Ioannis G. Baraboutis
- Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities
[Abstract] [Full Text] [PDF]
- Christopher McGuigan and Jan Balzarini
- FV100 as a new approach for the possible treatment of varicella-zoster virus infection
[Abstract] [Full Text] [PDF]
- F. Martin and G. P. Taylor
- The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is ‘the more the merrier’?
[Abstract] [Full Text] [PDF]
- Matthew S. Dryden, Jonathan Cooke, and Peter Davey
- Antibiotic stewardship—more education and regulation not more availability?
[Abstract] [Full Text] [PDF]
- Gavin D. Barlow and on behalf of the BSAC Council
- Swine flu and antibiotics
[Abstract] [Full Text] [PDF]
- Gavin D. Barlow and on behalf of the BSAC Council
- Swine flu and antibiotics
[Abstract] [Full Text] [PDF]
- Asgeir Johannessen, Marius Troseid, and Alexandra Calmy
- Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings
[Abstract] [Full Text] [PDF]
- Matthew Dryden, Kieran Hand, Peter Davey, and on behalf of the BSAC Council
- Antibiotics for community-acquired pneumonia
[Abstract] [Full Text] [PDF]
- Martin Vogel and Jurgen K. Rockstroh
- Treatment of acute hepatitis C in HIV infection
[Abstract] [Full Text] [PDF]
- Douglas G. Altman and Iveta Simera
- Responsible reporting of health research studies: transparent, complete, accurate and timely
[Abstract] [Full Text] [PDF]
- Julie Sheldon and Vincent Soriano
- Hepatitis B virus escape mutants induced by antiviral therapy
[Abstract] [Full Text] [PDF]
- Hong Zhang
- Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza
[Abstract] [Full Text] [PDF]
- I. M. Gould
- Antibiotic policies to control hospital-acquired infection
[Abstract] [Full Text] [PDF]
- Benedicte Roquebert and Anne-Genevieve Marcelin
- The involvement of HIV-1 RNAse H in resistance to nucleoside analogues
[Abstract] [Full Text] [PDF]
- Linos Vandekerckhove, Chris Verhofstede, and Dirk Vogelaers
- Maraviroc: integration of a new antiretroviral drug class into clinical practice
[Abstract] [Full Text] [PDF]
- Linos Vandekerckhove, Chris Verhofstede, and Dirk Vogelaers
- Maraviroc: integration of a new antiretroviral drug class into clinical practice
[Abstract] [Full Text] [PDF]
- Vincent Soriano, Alan S. Perelson, and Fabien Zoulim
- Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
[Abstract] [Full Text] [PDF]
- Nidhi A. Singh and Nancy Reau
- Management of hepatitis B virus
[Abstract] [Full Text] [PDF]
- Xilin Zhao and Karl Drlica
- A unified anti-mutant dosing strategy
[Abstract] [Full Text] [PDF]
- S. Harbarth and M. H. Samore
- Interventions to control MRSA: high time for time-series analysis?
[Abstract] [Full Text] [PDF]
- Samson S. Y. Wong and Kwok-Yung Yuen
- The management of coronavirus infections with particular reference to SARS
[Abstract] [Full Text] [PDF]
- Anna Maria Geretti
- Shifting paradigms: the resistance profile of etravirine
[Abstract] [Full Text] [PDF]
- Rachel Hilton and C. Y. William Tong
- Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation
[Abstract] [Full Text] [PDF]
- David Richard Phillips and Phillip Hay
- Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy
[Abstract] [Full Text] [PDF]
- Johannes Wiegand, Katja Deterding, Markus Cornberg, and Heiner Wedemeyer
- Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon
[Abstract] [Full Text] [PDF]
- Cliodna A. M. McNulty and Alan P. Johnson
- The European Antibiotic Awareness Day
[Abstract] [Full Text] [PDF]
- Tzu-Chun Chen, Kuo-Feng Weng, Shih-Cheng Chang, Jing-Yi Lin, Peng-Nien Huang, and Shin-Ru Shih
- Development of antiviral agents for enteroviruses
[Abstract] [Full Text] [PDF]
- Christian G. Giske, Arnfinn S. Sundsfjord, Gunnar Kahlmeter, Neil Woodford, Patrice Nordmann, David L. Paterson, Rafael Canton, and Timothy R. Walsh
- Redefining extended-spectrum β-lactamases: balancing science and clinical need
[Abstract] [Full Text] [PDF]
- Matthew D. Marsden and Jerome A. Zack
- Eradication of HIV: current challenges and new directions
[Abstract] [Full Text] [PDF]
- G. Gopal Rao and Mehool Patel
- Urinary tract infection in hospitalized elderly patients in the United Kingdom: the importance of making an accurate diagnosis in the post broad-spectrum antibiotic era
[Abstract] [Full Text] [PDF]
- Neil Woodford, David W. Wareham, and on behalf of the UK Antibacterial Antisense Study Group
- Tackling antibiotic resistance: a dose of common antisense?
[Abstract] [Full Text] [PDF]
- J. M. Blondeau
- What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?
[Abstract] [Full Text] [PDF]
- J. M. Blondeau
- What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?
[Abstract] [Full Text] [PDF]
- Robert W. Burgoyne and Darrell H. S. Tan
- Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
[Abstract] [Full Text] [PDF]
- Robert W. Burgoyne and Darrell H. S. Tan
- Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
[Abstract] [Full Text] [PDF]
- Timothy Edgar, Stephanie D. Boyd, and Megan J. Palame
- Sustainability for behaviour change in the fight against antibiotic resistance: a social marketing framework
[Abstract] [Full Text] [PDF]
- David M. Livermore and Paul M. Tulkens
- Temocillin revived
[Abstract] [Full Text] [PDF]
- Ian Chopra
- The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?
[Abstract] [Full Text] [PDF]
- Sebastian G. B. Amyes, Fiona M. Walsh, and John S. Bradley
- Best in class: a good principle for antibiotic usage to limit resistance development?
[Abstract] [Full Text] [PDF]
- Carmen Y. Lim and Kris V. Kowdley
- Optimal duration of therapy in HBV-related cirrhosis
[Abstract] [Full Text] [PDF]
- Guangbi Yao
- Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China
[Abstract] [Full Text] [PDF]
- Guangbi Yao
- Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China
[Abstract] [Full Text] [PDF]
- Nicolai Lohse, Ann-Brit Eg Hansen, Jan Gerstoft, and Niels Obel
- Improved survival in HIV-infected persons: consequences and perspectives
[Abstract] [Full Text] [PDF]
- Robert G. Masterton and Michele Caldwell
- Improving practice—the Hospital Pharmacy Initiative revisited
[Abstract] [Full Text] [PDF]
- Hanneke K. A. Knaapen and Pilar Barrera
- Therapy for Whipple's disease
[Abstract] [Full Text] [PDF]
- Darius Armstrong-James
- Invasive Candida species infection: the importance of adequate empirical antifungal therapy
[Abstract] [Full Text] [PDF]
- Jonathan Cooke, Peter Davey, Hayley Wickens, Ann Jacklin, Conor Jamieson, Ysobel Gourlay, Kieran Hand, and Sally Wellsteed
- Improving practice—working together to improve the use of antimicrobials
[Abstract] [Full Text] [PDF]
- Pierre-Louis Toutain, Alain Bousquet-Melou, and Marilyn Martinez
- AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?
[Abstract] [Full Text] [PDF]
- Nicola Price and Elizabeth H. Boxall
- Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression
[Abstract] [Full Text] [PDF]
- Leonard Leibovici and Mical Paul
- Aminoglycoside/ß-lactam combinations in clinical practice
[Abstract] [Full Text] [PDF]
- B. Cherie Millar, Bernard D. Prendergast, and John E. Moore
- Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis
[Abstract] [Full Text] [PDF]
- Caroline Foster and Hermione Lyall
- HIV and mitochondrial toxicity in children
[Abstract] [Full Text] [PDF]
- Bonaventura Clotet
- Once-daily dosing of nevirapine in HAART
[Abstract] [Full Text] [PDF]
- Neil Woodford
- Successful, multiresistant bacterial clones
[Abstract] [Full Text] [PDF]
- Katherine Samaras
- Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
[Abstract] [Full Text] [PDF]
- Johan W. Mouton, Ursula Theuretzbacher, William A. Craig, Paul M. Tulkens, Hartmut Derendorf, and Otto Cars
- Tissue concentrations: do we ever learn?
[Abstract] [Full Text] [PDF]
- William E. Delaney IV
- Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil
[Abstract] [Full Text] [PDF]
- Andrew Lucas, David Nolan, and Simon Mallal
- HLA-B*5701 screening for susceptibility to abacavir hypersensitivity
[Abstract] [Full Text] [PDF]
- Pablo Barreiro and Vincent Soriano
- Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
[Abstract] [PDF]
- S. F. Stone, P. Price, and M. A. French
- Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease
[Abstract] [PDF]
- Vincent Soriano, Pablo Barreiro, and Marina Nunez
- Management of chronic hepatitis B and C in HIV-coinfected patients
[Abstract] [PDF]
- Flavia B. Lillo and Caterina Uberti-Foppa
- Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women
[Abstract] [PDF]
- Patricia K. Lee, Tara L. Kieffer, Robert F. Siliciano, and Richard E. Nettles
- HIV-1 viral load blips are of limited clinical significance
[Abstract] [PDF]
- Matthew J. Ellington and Neil Woodford
- Fluoroquinolone resistance and plasmid addiction systems: self-imposed selection pressure?
[Abstract] [PDF]
- Melissa K. Osborn and Anna S. F. Lok
- Antiviral options for the treatment of chronic hepatitis B
[Abstract] [PDF]
- Richard Wise
- Antimicrobial resistance: paradox, actions and economics
[Abstract] [PDF]
- Diego Rincon, Cristina Ripoll, Maria Vega Catalina, Magdalena Salcedo, and Rafael Banares
- Does interferon improve portal hypertension?
[Abstract] [PDF]
- Eugenia Negredo, Anna Bonjoch, and Bonaventura Clotet
- Benefits and concerns of simplification strategies in HIV-infected patients
[Abstract] [PDF]
- Mark A. Toleman, Peter M. Bennett, and Timothy R. Walsh
- Common regions e.g. orf513 and antibiotic resistance: IS91-like elements evolving complex class 1 integrons
[Abstract] [PDF]
- D. A. Mitchison
- Clinical development of anti-tuberculosis drugs
[Abstract] [PDF]
- Mauro Schechter and Suely Hiromi Tuboi
- Discordant immunological and virological responses to antiretroviral therapy
[Abstract] [PDF]
- Marco Bongiovanni, Maddalena Casana, Camilla Tincati, and Antonella d'Arminio Monforte
- Treatment interruptions in HIV-infected subjects
[Abstract] [PDF]
- Sumita Verma
- HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
[Abstract] [PDF]
- Vivienne Weston and Gerald Coakley
- Guideline for the management of the hot swollen joint in adults with a particular focus on septic arthritis
[Abstract] [PDF]
- Y. Horsmans
- Interferon-induced depression in chronic hepatitis C
[Abstract] [PDF]
- Jane Democratis, Manish Pareek, and Iain Stephenson
- Use of neuraminidase inhibitors to combat pandemic influenza
[Abstract] [PDF]
- F. Goldstein
- The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus
[Abstract] [PDF]
- Peter Davey
- The potential role of computerized decision support systems to improve empirical antibiotic prescribing
[Abstract] [PDF]
- Johan W. Mouton, Michael N. Dudley, Otto Cars, Hartmut Derendorf, and George L. Drusano
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
[Abstract] [PDF]
- Fabien Zoulim
- Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models
[Abstract] [PDF]
- Ramazan Idilman
- Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy
[Abstract] [PDF]
- Franco Maggiolo, Diego Ripamonti, and Fredy Suter
- Switch strategies in patients on effective HAART
[Abstract] [PDF]
- Robert W. Shafer and Jonathan M. Schapiro
- Drug resistance and antiretroviral drug development
[Abstract] [PDF]
- Angel Luis Ballesteros, Daniel Fuster, Ramon Planas, Bonaventura Clotet, and Cristina Tural
- Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients
[Abstract] [PDF]
- Ana Milinkovic and Esteban Martinez
- Current perspectives on HIV-associated lipodystrophy syndrome
[Abstract] [PDF]
- Alan Winston and Marta Boffito
- The management of HIV-1 protease inhibitor pharmacokinetic interactions
[Abstract] [PDF]
- J. Gerardo Garcia-Lerma
- Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons
[Abstract] [PDF]
- Neil Woodford and Arnfinn Sundsfjord
- Molecular detection of antibiotic resistance: when and where?
[Abstract] [PDF]
- Kurt Vermeire and Dominique Schols
- Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs
[Abstract] [PDF]
- Susan S. Kaplan and Charles B. Hicks
- Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection
[Abstract] [PDF]
- Pentti Huovinen
- Mathematical model--tell us the future!
[Abstract] [PDF]
- Catherine Yates and Sebastian Amyes
- Extended-spectrum
-lactamases in non-typhoidal Salmonella spp. isolated in the UK are now a reality: why the late arrival?
[Abstract] [PDF]
- Edward Gershburg and Joseph S. Pagano
- Epstein-Barr virus infections: prospects for treatment
[Abstract] [PDF]
- Tamiko Hisanaga, Daryl J. Hoban, and George G. Zhanel
- Mechanisms of resistance to telithromycin in Streptococcus pneumoniae
[Abstract] [PDF]
- S. Mauss and J. K. Rockstroh
- HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?
[Abstract] [PDF]
- David M. Livermore
- Tigecycline: what is it, and where should it be used?
[Abstract] [PDF]
- Ronald B. Turner and J. Owen Hendley
- Virucidal hand treatments for prevention of rhinovirus infection
[Abstract] [PDF]
- S. F. FitzGerald, C. Kelly, and H. Humphreys
- Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus
[Abstract] [PDF]
- Norbert Brau
- Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy
[Abstract] [PDF]
- Robert G. Gish
- Treating HCV with ribavirin analogues and ribavirin-like molecules
[Abstract] [PDF]
- Sophie Grabar, Laurence Weiss, and Dominique Costagliola
- HIV infection in older patients in the HAART era
[Abstract] [PDF]
- Susan Brown and Sebastian Amyes
- OXA -lactamases in Acinetobacter: the story so far
[Abstract] [PDF]
- R. Scott McClelland and Jared M. Baeten
- Reducing HIV-1 transmission through prevention strategies targeting HIV-1-seropositive individuals
[Abstract] [PDF]
- Samuel A. Shelburne, Martin Montes, and Richard J. Hamill
- Immune reconstitution inflammatory syndrome: more answers, more questions
[Abstract] [PDF]
- Jan Balzarini, Miguel Stevens, Erik De Clercq, Dominique Schols, and Christophe Pannecouque
- Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action
[Abstract] [PDF]
- Hans-Ulrich Bernard
- Established and potential strategies against papillomavirus
infections
[Abstract] [PDF]
- Ben de Pauw
- Preventative use of antifungal drugs in patients
treated for cancer
[Abstract] [PDF]
- Emilio Fumero, Felipe Garcia, and J. M. Gatell
- Immunosuppressive drugs as an adjuvant to HIV treatment
[Abstract] [PDF]
- Victor E. Buckwold
- Implications of finding synergic in
vitro drug-drug interactions between interferon- and ribavirin for the treatment of
hepatitis C virus
[Abstract] [PDF]
- Spotswood L. Spruance and Joanne Hill
- Clinical significance of antiviral therapy for
episodic treatment
of herpes labialis: exploratory analyses of the combined data
from two valaciclovir trials
[Abstract] [PDF]
- Douglas D. Richman
- Benefits and limitations of testing for resistance
to HIV drugs
[Abstract] [PDF]
- J. K. Rockstroh and S. Mauss
- Clinical perspective of fusion inhibitors for treatment
of HIV
[Abstract] [PDF]
- David R. Bangsberg, Andrew R. Moss, and Steven G. Deeks
- Paradoxes of adherence and drug resistance to HIV
antiretroviral therapy
[Abstract] [PDF]
- A. D. Russell
- Whither triclosan?
[Abstract] [PDF]
- Lance R. Peterson and Axel Dalhoff
- Towards targeted prescribing: will the cure for
antimicrobial resistance be specific, directed therapy through improved
diagnostic testing?
[Abstract] [PDF]
- Golo Ahlenstiel, Rainer P. Woitas, Jurgen Rockstroh, and Ulrich Spengler
- CC-chemokine receptor 5 (CCR5) in hepatitis C--at
the crossroads of the antiviral immune response?
[Abstract] [PDF]
- Conan MacDougall and B. Joseph Guglielmo
- Pharmacokinetics of valaciclovir
[Abstract] [PDF]
- Mike Bray and Chad J. Roy
- Antiviral prophylaxis of smallpox
[Abstract] [PDF]
- Amanda Mocroft and Jens D. Lundgren
- Starting highly active antiretroviral therapy: why, when and response to HAART
[Abstract] [PDF]
- Janet D. Siliciano and Robert F. Siliciano
- A long-term latent reservoir for HIV-1: discovery and clinical implications
[Abstract] [PDF]
- Norbert Hubert Gruener, Maria-Christina Jung, and Carl Albrecht Schirren
- Recurrent hepatitis C virus infection after liver transplantation: natural course, therapeutic approach and possible mechanisms of viral control
[Abstract] [PDF]
- Robert T. Sarisky
- Non-nucleoside inhibitors of the HCV polymerase
[Abstract] [PDF]
- T. M. A. Weller and C. E. Jamieson
- The expanding role of the antibiotic pharmacist
[Abstract] [PDF]
- Philip J. Budge and Barney S. Graham
- Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses
[Abstract] [PDF]
- Heiner C. Bucher, James Young, and Manuel Battegay
- Protease inhibitor-sparing simplified maintenance therapy: a need for perspective
[Abstract] [PDF]
- Kathryn L. Springer and Adriana Weinberg
- Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity
[Abstract] [PDF]
- Javier Rojo and Rafael Delgado
- Glycodendritic structures: promising new antiviral drugs
[Abstract] [PDF]
- Daniel K. Benjamin Jr, Steven Hirschfeld, Coleen K. Cunningham, and Ross E. McKinney Jr
- Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials
[Abstract] [PDF]
- Chien-Ching Hung and Shan-Chwen Chang
- Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections
[Abstract] [PDF]
- Robert G. Masterton
- Antibiotic cycling: more than it might seem?
[Abstract] [PDF]
- Norio Akuta and Hiromitsu Kumada
- Influence of hepatitis B virus genotypes on the response to antiviral therapies
[Abstract] [PDF]
- Justin Stebbing, Philip Savage, Steve Patterson, and Brian Gazzard
- All for CD91 and CD91 for all
[Abstract] [PDF]
- John P. Moore and Robin J. Shattock
- Preventing HIV-1 sexual transmission--not
sexy enough science, or no benefit to the bottom line?
[PDF]
- Leonardo Calza, Roberto Manfredi, and Francesco Chiodo
- Dyslipidaemia associated with antiretroviral therapy
in HIV-infected patients
[Abstract] [PDF]
- Peter Ferenci
- Predicting the therapeutic response in patients
with chronic
hepatitis C: the role of viral kinetic studies
[Abstract] [PDF]
- Fang Fang and Mang Yu
- Viral receptor blockage by multivalent recombinant
antibody fusion proteins: inhibiting human rhinovirus (HRV) infection
with CFY196
[Abstract] [PDF]
- Elisabeta Vergu, Alain Mallet, and Jean-Louis Golmard
- Available clinical markers of treatment outcome
integrated in mathematical models to guide therapy in HIV infection
[Abstract] [PDF]
- Robert K. Zeldin and Richard A. Petruschke
- Pharmacological and therapeutic properties of ritonavir-boosted protease
inhibitor therapy in HIV-infected patients
[Abstract] [PDF]
- Keisuke Hino and Kiwamu Okita
- Interferon therapy as chemoprevention of hepatocarcinogenesis
in patients with chronic hepatitis C
[Abstract] [PDF]
- Louis Bernard, Pierre Hoffmeyer, Mathieu Assal, Pierre Vaudaux, Jacques Schrenzel, and Daniel Lew
- Trends in the treatment of orthopaedic prosthetic
infections
[Abstract] [PDF]
- Beverley C. Millar and John E. Moore
- Antibiotic prophylaxis, body piercing and infective
endocarditis
[Abstract] [PDF]
- John Oxford, Shobana Balasingam, and Rob Lambkin
- A new millennium conundrum: how to use a powerful
class of influenza anti-neuraminidase drugs (NAIs) in the community
[Abstract] [PDF]
- Damian J. McColl and Michael D. Miller
- The use of tenofovir disoproxil fumarate for the
treatment of nucleoside-resistant HIV-1
[PDF]
- Man-Fung Yuen and Ching-Lung Lai
- Current and future antiviral agents for chronic
hepatitis B
[PDF]
- Samuel S. Lee and Ayman A. Abdo
- Predicting antiviral treatment response in chronic
hepatitis C:
how accurate and how soon?
[PDF]
- Patrick G. Hoggard and Andrew Owen
- The mechanisms that control intracellular penetration
of the HIV protease inhibitors
[PDF]
- Glen A. Coburn and Bryan R. Cullen
- siRNAs: a new wave of RNA-based therapeutics
[PDF]
- Scott D. Mills
- The role of genomics in antimicrobial discovery
[PDF]
- Erik De Clercq
- New inhibitors of human cytomegalovirus (HCMV)
on the horizon
[PDF]
- Marla J. Keller, Mary E. Klotman, and Betsy C. Herold
- Rigorous pre-clinical evaluation of topical microbicides
to prevent transmission of human immunodeficiency virus
[PDF]
- F. Van Bambeke, Y. Glupczynski, P. Plesiat, J. C. Pechere, and P. M. Tulkens
- Antibiotic efflux pumps in prokaryotic cells: occurrence,
impact on resistance and strategies for the future of antimicrobial
therapy
[PDF]
- F. Van Bambeke, J.-M. Michot, and P. M. Tulkens
- Antibiotic efflux pumps in eukaryotic cells: occurrence
and impact on antibiotic cellular pharmacokinetics, pharmacodynamics
and toxicodynamics
[PDF]
- Naohiro Kamiya
- The mechanisms of action of antivirals against
hepatitis B virus infection
[PDF]
- Beatrice Macchi, Emanuela Balestrieri, and Antonio Mastino
- Effects of nucleoside-based antiretroviral chemotherapy
on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1)
infection in vitro
[PDF]
- Heather J. Smith, Kimberly A. Nichol, Daryl J. Hoban, and George G. Zhanel
- Stretching the mutant prevention concentration
(MPC) beyond its limits
[PDF]
- Noboru Uchide and Kunio Ohyama
- Antiviral function of pyrrolidine dithiocarbamate
against influenza virus: the inhibition of viral gene replication
and transcription
[PDF]
- Nancy D. Hanson
- AmpC -lactamases:
what do we need to know for the future?
[PDF]
- K. Kummerer
- Significance of antibiotics in the environment
[PDF]
- Michelle Swanson-Mungerson, Masato Ikeda, Lori Lev, Richard Longnecker, and Toni Portis
- Identification of latent membrane protein 2A (LMP2A)
specific targets for treatment and eradication of Epstein-Barr
virus (EBV)-associated diseases
[PDF]
- Rafael de la Rosa and Manuel Leal
- Thymic involvement in recovery of immunity among
HIV-infected adults on highly active antiretroviral therapy
[PDF]
- Gunnar Kahlmeter, Derek F. J. Brown, Fred W. Goldstein, Alasdair P. MacGowan, Johan W. Mouton, Anders Osterlund, Arne Rodloff, Martin Steinbakk, Pavla Urbaskova, and Alkiviadis Vatopoulos
- European harmonization of MIC breakpoints for antimicrobial susceptibility
testing of bacteria
[PDF]
- Shiou-Hwei Yeh, Ding-Shinn Chen, and Pei-Jer Chen
- A prospect for pharmacogenomics in the interferon
therapy of chronic viral hepatitis
[PDF]
- Nancy A. Jewell, Renxiang Chen, Raquel Raices, and Louis M. Mansky
- Nucleoside reverse transcriptase inhibitors and
HIV mutagenesis
[PDF]
- Denise Paulsen, Robert Elston, Wendy Snowden, Margaret Tisdale, and Lisa Ross
- Differentiation of genotypic resistance profiles
for amprenavir and lopinavir, a valuable aid for choice of therapy
in protease inhibitor-experienced HIV-1-infected subjects
[PDF]
- Pramod M. Shah and Robin D. Isaacs
- Ertapenem, the first of a new group of carbapenems
[PDF]
- Jim Zhen Wu, Chin-chung Lin, and Zhi Hong
- Ribavirin, viramidine and adenosine-deaminase-catalysed
drug activation: implication for nucleoside prodrug design
[PDF]
- A. Fraternale, A. Casabianca, L. Rossi, L. Chiarantini, G. F. Schiavano, A. T. Palamara, E. Garaci, and M. Magnani
- Erythrocytes as carriers of reduced glutathione
(GSH) in the treatment of retroviral infections
[PDF]
- Anthony Kebba
- Antiretroviral therapy in sub-Saharan Africa: myth
or reality?
[PDF]
- Johannes A. Bogaards and Jaap Goudsmit
- Meeting the immense need for HAART in resource-poor
settings
[PDF]
- Melissa M. Herbst and Richard B. Pyles
- Immunostimulatory CpG treatment for genital HSV-2
infections
[PDF]
- Shirit Einav and Jeffrey S. Glenn
- Prenylation inhibitors: a novel class of antiviral
agents
[Abstract] [PDF]
- John Turnidge
- Antibiotic use in animals--prejudices,
perceptions and realities
[Abstract] [PDF]
- L. P. GARROD
- Forty years on
J. Antimicrob. Chemother. 1975. 1:1-2.[PDF]
- J. D. WILLIAMS
- Editorial
J. Antimicrob. Chemother. 1975. 1:1-1.[PDF]
- H. P. LAMBERT
- Unwanted effects of antibiotics: some recent additions
J. Antimicrob. Chemother. 1975. 1:2-4.[PDF]
- RICHARD WISE
- For and against carfecillin—a matter of resistance?
J. Antimicrob. Chemother. 1975. 1:4-5.[PDF]